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1. Summary 
Cells have developed many mechanisms to repair alterations of the DNA, but in the 
adaptive immune system, the immunoglobulin (Ig) gene diversification processes of the B 
lymphocytes require drastic genetic changes. Activation induced cytidine deaminase (AID) is 
the key enzyme involved in the secondary diversification of the Ig genes by somatic 
hypermutation (SHM) or class switch recombination (CSR). Recently, it was found that AID 
acts in a genome wide manner and the ultimate distribution of mutations is achieved by locus 
specific regulation of error-prone and error-free DNA repair. 
The Rad6 pathway is known to be the molecular switch between error-prone and error-
free DNA repair during replication. Rad18 is a key mediator of the Rad6 pathway and also 
plays a role in SHM and in the ubiquitination of the 9-1-1 checkpoint DNA clamp. These 
emerging evidences of Rad18 as a central player of DNA damage recognition, response and 
repair makes it an interesting candidate to explore its interaction network. 
 The aim of this work was to study the Rad18 interaction network in DT40 cells by 
combination of a contemporary biochemical tool – tandem affinity purification (TAP) with 
the versatile DT40 cell system, followed by mass spectrometric analysis. 
The approach was established successfully using AID-TAP fusion constructs as a model 
system and was subsequently transferred to the study of the Rad18 interaction network. The 
Rad18-HA-TAP tagged constructs were expressed in rad18
-/-
 DT40 cells and the fusions were 
characterised for expression, localisation, complex formation and functionality. Subsequently, 
the TAP technique was employed to isolate the Rad18 interaction complex, which was then 
analysed by LC-MALDI analysis. The bait protein and known interaction partners were 
identified in the analysis. There were also interesting new interactions identified, some of 
which were known to be linked to the JNK pathway. Functional analyses were carried out to 
test the activation of JNK pathway upon MMS induced DNA damage in different sets of 
Rad18 proficient and deficient DT40 cells. These assays revealed a novel function of Rad18 
in the activation of JNK pathway upon DNA damage induced stalled replication and also 
implied that this function of Rad18 does not require the RING domain of RAD18 and the 
ubiquitination of PCNA. 
This novel function of Rad18 in the JNK pathway may imply a possible mechanism of 
regulation of cell fate towards survival or apoptosis. Future studies would be focussed on 
characterising this novel function by mutational analysis of Rad18 and a more sensitive 
proteomic approach to pinpoint the interaction partner(s) that may be involved in this function 
of Rad18.  
 2 
2. Introduction 
The genome of a cell is often subject to alterations by exogenous challenges such as 
ultraviolet or ionizing radiation and certain chemicals that damage DNA. Endogenous 
processes also contribute to DNA damage, such as base oxidation and strand breaks induced 
by reactive oxygen species, the spontaneous depurination/ depyrimidination of DNA by 
hydrolysis, replication defects resulting in mismatches, and the collapse of replication forks 
leading to strand breaks. DNA damage can be broadly classified into four types based on the 
type of modification of the DNA, namely 1) base modifications such as alkylation, 
deamination etc, 2) mismatches of bases on opposite strands, 3) single and double strand 
breaks and 4) interstrand and intrastrand crosslinks. These damages are often deleterious to 
the cell when they are left unrepaired, since they may result in blockage of transcription and 
replication, mutagenesis and/or cytotoxicity (Friedberg 1995). In humans, defective repair of 
DNA damage is associated with a variety of hereditary disorders, aging and carcinogenesis 
(Finkel and Holbrook 2000; Hoeijmakers 2001; Peltomaki 2001). Under normal conditions, 
the DNA damage is repaired by various mechanisms depending on the type of damage, and in 
proliferating cells, the repair is carried out in concert with cell cycle regulation. 
When damage to the genome is recognized, DNA damage checkpoints are activated by 
the ATM (ataxia telangiectasia, mutated) and/or ATR (ATM and Rad3 related) protein 
kinases (Abraham 2001; Shiloh 2003) by primarily protein phosphorylation events from the 
factors detecting the damage to the cell cycle targets downstream. The cell cycle progression 
is halted at the G1/S transition, intra-S phase and the G2/M transition checkpoints and is 
coordinated with several biochemical pathways that respond to the damage and repair the 
DNA structure (Bartek and Lukas 2007). The checkpoints delay DNA replication and mitosis 
for the repair of the damage. All these processes are coordinated to achieve faithful 
maintenance, replication and segregation of the genetic material. 
Figure 1 represents an instance of such a regulation starting with the processing of DNA 
adducts in the G1 phase. The various mechanisms of repair that are engaged to process the 
different types of damaged structures are also depicted. The failure to repair adducts before 
the G1/S checkpoint could trigger p53 induced apoptosis (Lowe et al. 2004). On the other 
hand, the subsequent entry of damaged DNA into the S-phase would lead to stalling of 
replication forks. The intra-S-phase checkpoint halts the cell cycle at this point and the 
enzymes of the Rad6 pathway are recruited to the stalled fork (Broomfield et al. 2001). This 
pathway is the molecular switch between bypass of the damage either by error-prone 
translesion synthesis (TLS) or by error-free bypass of the lesion by a template switch  
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mechanism (Broomfield et al. 2001). In the event of persistent damage, the stalled replication 
fork may collapse during repair, giving rise to strand breaks. Strand breaks may also arise 
when cells are exposed to ionizing radiation, free radicals and certain genotoxic chemicals. 
The double strand breaks (DSB) may be repaired by non-homologous end joining (NHEJ) or 
by homologous recombination (HR). Aberrant DSB repair could lead to chromosomal 
translocations. While the persistence of damage from one cell cycle phase to the next can lead 
to the generation of secondary damaged structures, it must be noted that the types of DNA 
damage are not strictly confined to a particular cell cycle phase. 
2.1. Mechanisms of DNA repair 
The repair of the DNA damage generally involves recognition, isolation and removal of 
the damage, followed by DNA synthesis and ligation. The direct reversal of base damage, 
base excision repair (BER), nucleotide excision repair (NER) and mismatch repair (MMR) are 
simple yet very important DNA repair mechanisms. Besides these mechanisms, there are also 
Figure 1: Coordination of the cell cycle checkpoints with DNA damage processing 
The figure depicts a generalised representation of the processing of various forms of DNA 
damage (starting from DNA adducts in the G1 phase) by different repair mechanisms in concert 
with the cell cycle regulation by cell cycle checkpoints. See details in text. Abbreviations: G1 – 
Gap1, S – Synthetic, G2 – Gap2 and M – Mitotic phases of the cell cycle; DSB – double strand 
break. 
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certain intricate repair pathways, i.e. the replication associated repair and the DSB repair 
pathways. 
The direct reversal of base damage is the simplest of the human DNA repair pathways 
involving the direct reversal of the highly mutagenic alkylation lesion O6-methylguanine (O6-
mG) adduct via the action of the enzyme O6-methylguanine DNA methyltransferase 
(MGMT) (Margison and Santibanez-Koref 2002). The O6-mG adduct is generated at low 
levels by the reaction of cellular catabolites with guanine residues in the DNA (Sedgwick 
1997). The base is corrected by the direct transfer of the alkyl group from the guanine base to 
the cysteine residue in the active site of MGMT, which is then degraded by an ATP-
dependent proteolytic pathway (Srivenugopal et al. 1996), requiring a new molecule of the 
MGMT protein for every methyl group. 
BER is a multi-step process that restores non-bulky base damages resulting from 
methylation, oxidation, deamination, or spontaneous loss of the DNA base itself (Memisoglu 
and Samson 2000). Although these alterations are simple in nature, they are highly mutagenic 
and hence represent a significant threat to genome fidelity and stability (Friedberg 1995). The 
action of DNA glycosylases removes the damaged base (Lindahl 1974) followed by incision 
of the abasic site by apurinic/apyrimidinic (AP) endonuclease. The gap is then filled by DNA 
synthesis by either a short patch repair if the gap is single nucleotide (Matsumoto et al. 1999) 
or by a long patch repair if the gap is 2-8 nucleotides in size (Pascucci et al. 1999). The short 
patch repair involves the synthesis of a single nucleotide into the abasic site and is carried out 
by Polβ and represents the major route of BER (Fortini et al. 1998). The long-patch repair is 
the back-up pathway of BER and is employed when a modified base resistant to the AP lyase 
activity of the Polβ is present in the DNA (Matsumoto et al. 1994). The long patch base 
excision repair is mediated by Polδ and Polε (Stucki et al. 1998). Subsequently the strand nick 
is ligated by a DNA ligase, thereby restoring the integrity of the DNA. 
NER is capable of acting on diverse DNA lesions and the pyrimidine dimers caused by 
UV are the most significant of these lesions. Bulky chemical adducts, intrastrand crosslinks 
and some forms of oxidative damage are other forms of lesions that are substrates of NER. 
The common features of the lesions recognized by NER are that they cause distortion of the 
DNA helix and a modification of the DNA chemistry (Hess et al. 1997). During NER, the 
damage is removed along with several nucleotides flanking it and the gap is filled by normal 
DNA synthesis and ligation (de Laat et al. 1999). NER is executed either as a global repair 
which repairs lesions over the entire genome, or also as transcription coupled repair that 
processes transcription-blocking lesions present in transcribed DNA strands (de Laat et al. 
Introduction 
 
5 
1999). Xeroderma Pigmentosum is a rare inherited disease caused by mutations in any one of 
the several genes involved in NER (Cleaver 1968). Defects in two of the genes involved in the 
transcription coupled NER are implicated in an inherited disorder called Cockayne‟s 
syndrome (Mullenders et al. 1988). 
The MMR pathway plays an essential role in the correction of replication errors such as 
mispaired bases or helix distorting insertion/deletion loops in the DNA duplex that result from 
misincorporation of nucleotides and template slippage, respectively. The repair is carried out 
by exonuclease digestion of the damaged strand, followed by DNA repair synthesis and re-
ligation (Marti et al. 2002). Mutations in several human MMR genes cause a predisposition to 
hereditary nonpolyposis colorectal cancer, as well as a variety of sporadic tumors that display 
microsatellite instability (Peltomaki 2001). BER, NER and MMR are error-free repair 
mechanisms, as the newly synthesized bases are added complementary to the opposite strand.  
In normal vertebrate cells, 6-4 photoproducts are efficiently repaired by NER, but nearly 
50% of cyclobutane pyrimidine dimers remain unrepaired even at 24h after UV irradiation 
(Mitchell and Nairn 1989). In such cases, the DNA replication machinery often encounters 
errors during S-phase and stalls the replication fork, resulting in a gap opposite the site of 
damage in the newly synthesized strand. The Rad6 pathway is engaged when the replication 
fork stalls to fill this gap and is mediated via bypassing the lesion by TLS or recombination to 
resolve the stalled replication fork (Broomfield et al. 2001). This pathway will be described in 
detail in section 2.7 of this thesis. 
Cells have evolved two distinct pathways to repair DSBs, namely HR and NHEJ. It 
appears that the choice between these pathways is largely influenced by the stage within the 
cell cycle at the time of damage acquisition (Takata et al. 1998). The HR-directed repair takes 
place in late S and G2 phases of the cell cycle when an undamaged sister chromatid is 
available for use as homologous template from which the genetic information is retrieved for 
an error-free repair. After the identification of the homologous DNA, the damaged DNA 
strand is synthesized from the information in the undamaged homologue. In contrast to HR, 
NHEJ does not require a homologous template for DSB repair and the strand break is usually 
corrected by a direct ligation of broken ends in a potentially error-prone mechanism as 
sometimes loss of some DNA at the ends may occur. 
2.2. Adaptive genetic alterations – an advantage  
DNA repair mechanisms are able to mend most genetic changes before they become 
permanent mutations. Further mutations that are deleterious are often eliminated by natural 
selection. Yet, a basal level of mutations accumulate in the genome with a frequency of about 
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-9
mutations/bp/generation that may contribute to single nucleotide polymorphisms (SNPs), 
variations in the gene pool, new phenotypes and ultimately evolution whenever the mutations 
occur in the germline. Therefore, in order to help the organism to adapt to a changing 
environment, genetic alterations may be often tolerated to a certain extent or even may be a 
prerequisite. These are adaptive genetic changes that are advantageous to the survival of the 
organism. The lymphocytes of the adaptive immune system present a classic instance when 
mutations and genetic alterations are adaptive. The genes that code for antibodies (or Ig) have 
an unusual architecture that facilitates the generation of a diverse set of polypeptide products 
comparable to the diversity of existing antigens. 
2.3. The primary Ig diversification during early B cell development 
The B cell development occurs through several stages, throughout which genetic 
alterations occur during the following important events: V(D)J recombination, Ig gene 
conversion in some organisms, SHM and CSR (Figure 2). The Ig genes expressed by B cells 
comprising heavy and light chains with both constant (C) and variable (V) regions are 
encoded by the heavy chain gene on chromosome 14 (M. J. Hobart 1981) and the light chains 
kappa (κ) and lambda (λ) genes located on chromosome 2 and chromosome 22 (McBride et 
al. 1982), respectively, in humans. 
In humans and mice, genes for the variable region of the Ig are encoded in the genome by 
three distinct types of segments, namely variable (V), diversity (D) and joining (J) segments. 
The preimmune repertoire is established early in the B-cell development in the bone marrow 
by germline rearrangements of each one of the numerous V, D and J gene segments of Ig 
genes for heavy chain and the V and J segments for the light chains to produce B cells each of 
which expresses an unique B cell receptor (Figure 2). The critical lymphocyte specific 
enzymes, called recombination activating gene-1 and -2 (RAG1 and RAG2) are involved in 
the initial steps of V(D)J recombination (Janeway 2004). These enzymes associate with each 
other to recognize the recombination signal sequences that flank the V, D and J gene 
segments and induce DNA cleavage at these sequences. The resultant V regions encode the 
antigen binding sites of antibodies that are then expressed with the constant region on the 
surface of the B cells and its clonal progeny and define the future fate of the naïve B cells. 
In some organisms such as rabbits, cows, pigs, horse and chicken, the primary antibody 
diversification is achieved through Ig gene conversion of the V region. The Ig loci of chicken, 
for instance, consist of a single V and J segment, and in case of the heavy chain locus, about 
15 D segments (Reynaud et al. 1989). Therefore, the combinatorial Ig diversification that  
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occurs in humans and mice is not possible. Instead, there are pseudogenes for the V segment 
at the region 5‟ of the V segment at both the light- and heavy- chain Ig loci. They lack 
functional promoters and V(D)J recombination signal sequences and are often truncated 
(Reynaud et al. 1987; McCormack and Thompson 1990). These pseudoV genes (ψV) are used 
as templates in the Ig gene conversion process in the bursa of Fabricius, during which 
sequence information is incorporated by homologous recombination into the single active V 
gene (Reynaud et al. 1987; Carlson et al. 1990) (Figure 2). The naïve B cells circulate in the 
blood and lymph and are carried to the secondary lymphoid organs, the spleen and lymph 
nodes (Janis Kuby 2003). 
2.4. The secondary Ig diversification processes in the germinal center 
Following specific antigen recognition by its cognate B cell receptor and co-stimulation 
by T cells, the naïve B cells are activated and move to the center of the secondary lymphoid 
follicle together with some T helper cells, thereby forming a germinal center. The activated B 
Figure 2: Adaptive genetic alterations in the Ig heavy chain locus. See text for details. 
Abbreviations: Ig – immunoglobulin; AID – Activation induced cytidine deaminase; RAG –
Recombination activating gene; NHEJ – Non-homologous end joining; V – exons of the variable 
segments; D – exons of the diversity segments; J – exons of the joining segments; Cμ, Cδ, Cγ1, Cγ2a, 
Cγ2b, Cγ3, Cε and Cα – different exons of the constant segments; ψV – pseudo-V genes 
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cells undergo intense proliferation and appear in the germinal centers as a well defined dark 
zone that is distinct from the region that also contains the follicular dendritic cells called the 
light zone (Hanna 1964; Jacob et al. 1991). 
In mice, the B cells in lymph node germinal centers have been directly visualised by two-
photon laser-scanning microscopy, revealing that nearly all antigen-specific B cells 
participating in a germinal center reaction were motile within the germinal center and 
migrated bi-directionally between dark and light zones (Schwickert et al. 2007). The B cells 
encounter the antigens trapped on follicular dendritic cells in the germinal centers triggering 
the second wave of antibody diversification through several rounds of SHM and affinity 
maturation during which process the competition for T cells plays a dominant role in the 
selection of B cells with high affinity B cell receptors (Allen et al. 2007). SHM of the Ig loci 
in germinal center B cells introduces random, single base substitutions and rarely insertions or 
deletions (Figure 2). The process is initiated by the deamination of cytosine by AID and 
completed by error-prone processing of the resulting uracils by MMR and BER. 
In the germinal center, CSR, an intrachromosomal recombinatorial event, also ensures that 
the antigen binding site can be expressed in combination with any one of the constant (C) 
region genes to achieve many different effector functions and be distributed throughout the 
body, while the antigen specificity remains unchanged (Rajewsky 1996). During this process, 
the functional V(D)J segment is brought into proximity with the exons of downstream Ig 
constant regions (Cγ2b, Cγ2a, etc), while the exons of the IgM constant region is removed by 
recombinational deletion (Figure 2). Thus, the IgM antibody coding genes, specific for a 
given antigen, are transformed into genes encoding high-affinity antibodies such as an IgG, 
IgA, or IgE isotype. 
SHM and CSR are the secondary Ig diversification processes in mice and humans while in 
birds, Ig gene conversion and SHM seems to act cooperatively in the germinal center 
(Arakawa et al. 1996; Arakawa et al. 1998), Ig gene conversion being the predominant 
process (Li et al. 2004). CSR is also known to occur in the germinal center of chicken 
(Yasuda et al. 2003). V(D)J rearrangements, Ig gene conversion and CSR generate changes 
by combinations of existing gene segments, whereas SHM is a unique process that generates 
changes in the sequence by point mutations (Figure 2). AID has been identified as a major 
enzyme involved in of all the three processes – SHM, Ig gene conversion and CSR (Honjo et 
al. 2004). While all the three processes are initiated by AID, the processing of the AID 
induced lesions are different for each process. 
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2.4.1. Processing of AID induced DNA lesions during adaptive immunity  
Initially, AID was thought to be an RNA-editing enzyme, owing to the homology of its 
active site to the catalytic site of other RNA editing enzymes such as APOBEC1 (Muramatsu 
et al. 1999; Muramatsu et al. 2000). However subsequent studies revealed that AID is a DNA 
editing enzyme (Pasqualucci et al. 2001; Bransteitter et al. 2003; Pham et al. 2003; Li et al. 
2004). The role of AID as the initiating factor in SHM and CSR was confirmed by studies 
showing that AID knockout mice were unable to carry out SHM and CSR similar to the 
patients with type II hyper-IgM immunodeficiency syndrome (Revy et al. 2000; Honjo et al. 
2004). The role of AID in Ig gene conversion has also been established (Arakawa et al. 2002). 
The AID protein has been well characterized and it has been suggested that the function of 
AID in SHM and CSR requires the interaction of AID with specific cofactors at distinct 
domains of AID (Shinkura et al. 2004). 
AID deaminates dC:dG pairs in the vicinity of either the IgV or Ig switch regions 
generating dU:dG lesions in the DNA (Rada et al. 2004). Figure 3 shows a schematic 
representation of the model for the processing of AID induced lesions. The dU:dG mismatch 
generated by AID may be further processed in three different ways. The mispair may be 
simply replicated over, leading to transition mutations at dC:dG pairs which may be grouped 
as phase 1A of SHM. The dU:dG mismatch may also be recognized by the mismatch repair 
enzymes MSH2/MSH6, generating dA:dT by mutagenic patch repair of the dU:dG lesion (or 
of derivatives thereof). These dA:dT biased mutations contribute to the phase 2 of the SHM 
model. The dU:dG mispair may also be subjected to uracil excision by uracil N-glycosylase 
(UNG), leading further to BER mediated repair of the abasic site thus generated. However, 
the UNG mediated base excision pathway is just one of the repair pathways following UNG 
action. Replication over the abasic site would yield both transitions and transversions at 
dC:dG (phase 1B). The pattern of gene diversification in UNG-deficient mice revealed that 
uracil excision by UNG played a dominant role in generating abasic sites upon which phase 
1B mutations were templated (Rada et al. 2004). When the activity of UNG was blocked, it 
resulted in blockage of Ig gene conversion in DT40 cells and a disconcerted SHM (Di Noia 
and Neuberger 2002; Di Noia and Neuberger 2004; Li et al. 2004; Saribasak et al. 2006). The 
abasic sites generated by UNG can also be subject to apurinic/apyrimidinic endonuclease 
(AP-endonuclease) cleavage that leads to a SSB, eventually leading to DSBs as the initial 
substrates for CSR, Ig gene conversion and deletions. 
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2.5. Targeting of somatic hypermutation to the Ig loci 
Earlier, most studies on the targeting of SHM conceptually centered on the targeting of 
AID by many factors, including transcription-coupled regulation and Ig enhancers (Bachl et 
al. 2001). The transcriptional machinery may regulate SHM either through interactions of 
various factors with the RNA polymerase complex or by alterations in the chromatin structure 
that may provide more access to potential mutator factor binding sites in the DNA. The Ig 
enhancers may regulate hypermutation by providing transcriptional activation of Ig loci 
and/or by containing cis-element(s) to target the AID mutator system. However, since most of 
the mutations in the V regions of the Ig genes are dependent on error prone repair, the 
recruitment of error-prone processing of the AID induced dU:dG mispair would also have to 
be regulated in addition to the targeting of AID to transcribed genes. Recently the non-Ig 
genes of the murine Peyer‟s patch B-cells of wild-type and AID-deficient mice littermates  
Figure 3: Model for repair of AID-induced lesions by somatic hypermutation, class switch 
recombination and Ig gene conversion (Rada et.al. 2004). See details in text. 
Abbreviations: AID – Activation induced cytidine deaminase; UNG – Uracil-N glycosylase; AP-
endonuclease – apurinic/apyrimidinic endonuclease; SHM – somatic hypermutation; CSR – class 
switch recombination; BER – base excision repair 
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were extensively sequenced (Liu et al. 2008). The mutational analysis showed that AID acts 
broadly on the transcribed genes in the mouse genome.The sequence analysis also showed 
that numerous genes linked to B-cell tumorigenesis, including Myc, Pim1, Pax5, Ocab, 
H2afx, Rhoh and Ebf1, are deaminated by AID but did not acquire mutations, apparently by 
the combined action of BER and MMR. The genome is thus protected by two distinct 
mechanisms, namely selective targeting of AID to transcribed genes and gene-specific, high-
fidelity repair of AID-generated uracils. However, approximately 25% of expressed genes 
analyzed were not fully protected by either mechanisms and accumulated mutations in 
Figure 4: Targeting of somatic hypermutation by locus-specific differential processing of AID-
induced lesions. The Phases 1A, 1B and 2 of SHM are depicted as proposed by the SHM model of 
Rada et al 2004. SHM involves error-prone BER and MMR mechanisms that may be preferentially 
targeted to the Ig loci. The error-free BER might contribute to the protection of the genome. The 
translesion synthesis to achieve SHM phase 1B and recruitment of Polη during dA/dT mutagenesis 
are regulated by the Rad6 pathway. Thus the Rad6 pathway may be the molecular regulator of the 
ultimate distribution of AID induced mutations in the B cell genome. 
Abbreviations: AID – Activation Induced Cytidine deaminase; UNG – Uracil-N glycosylase; AP-
endonuclease – Apurinic/Apyrimidinic Endonuclease; SHM – Somatic Hypermutation; CSR – 
class switch recombination; BER – base excision repair; MMR – mismatch repair 
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germinal centre B cells. These results indicated that the ultimate distribution of the AID 
induced mutations is determined by differential processing of AID induced lesions by a 
balance between high-fidelity DNA repair and error-prone DNA repairs. This observation in 
the context of the SHM model for the processing of AID mutations is summarized in figure 4. 
It is known that the Rad6 pathway is a molecular regulator of the switch between error-prone 
and error-free repair and is thus an interesting field of study. 
2.6. Role of the Rad6 pathway in Ig diversification processes 
The Rad6 pathway involves a heterogeneous group of enzymes that mediate error-prone 
and error-free repair of stalled replication forks, mediated by ubiquitination of PCNA 
(Lawrence 1994; Hoege et al. 2002). Nearly half of the known genes of the Rad6 epistasis 
group are enzymes of the ubiquitin system, and the remaining others mainly belong to the 
family of TLS polymerases (Jentsch et al. 1987; Ulrich and Jentsch 2000; Hoege et al. 2002). 
Many of the components of the Rad6 pathway have been found to be involved in one or more 
Ig diversification processes. The error-prone TLS polymerase, Polε is known to be an A:T 
mutator in SHM (Zeng et al. 2001). Another TLS polymerase encoded
 
by REV3 and REV7, 
Polδ is able to elongate mismatched base insertions and this property of Polδ is also utilized 
during SHM (Zan et al. 2001). Recently the key mediator of the Rad6 pathway – Rad18, was 
found to play a role in SHM (Bachl et al. 2006). The role of PCNA ubiquitination in SHM has 
also been substantiated in DT40 chicken B-cells (Arakawa et al. 2006). Also in mice, the A:T 
mutagenesis of SHM was shown to be strongly dependent on monoubiquitinated PCNA 
(PCNA
(ubi)
), since the PCNA
K164R/K164R
 mutant mice showed an altered SHM phenotype 
similar to Polε and MMR deficient B-cells, although the B cells could proliferate and perform 
CSR normally (Langerak et al. 2007). While Mms2, a ubiquitin conjugating enzyme that is 
involved in the error-free bypass of DNA lesion during the Rad6 pathway, is not required for 
efficient Ig gene conversion (Simpson and Sale 2005), a role of Rad18 in homologous 
recombination hints to a potential role of Rad18 in Ig gene conversion in DT40 chicken B-
cells (Szuts et al. 2006). Therefore, a role of the Rad6 pathway in templated and non-
templated Ig diversification is evident. 
2.7. The Rad6 Pathway 
The Rad6 pathway has been extensively characterized in yeast. Figure 5 shows an 
overview of the Rad6 pathway in yeast. Depending on the type of ubiquitination of PCNA, 
there are two subpathways, the TLS pathway and the error-free template switch repair. The 
monoubiquitination of PCNA triggers the TLS pathway while the polyubiquitination of 
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PCNA activates the error-free repair. Apart from recognition and repair of stalled replication 
forks, the Rad6 pathway is also known to be involved in dsDNA gap repair and Rad5 is 
involved in the avoidance of NHEJ during DSBR in yeast (Ahne et al. 1997; Moertl et al. 
2008). 
2.7.1. Translesion Synthesis 
The monoubiquitination of PCNA at lysine164 (K164) involves  the Rad6/Rad18 complex 
(Hoege et al. 2002). The Rad6 is an E2 ubiquitin conjugating enzyme (UBC) and Rad18 is an 
E3 ubiquitin ligase. The Rad18 protein forms a tight complex with Rad6 and associates with 
itself through the RING finger domain, forming a dimer of the Rad6/Rad18 heterodimer 
(Bailly et al. 1994; Xin et al. 2000; Miyase et al. 2005). Rad18 recruits the ubiquitinating 
Figure 5: The Rad6 Pathway in yeast. The ubiquitination status of PCNA serves as the molecular 
switch between error prone and error free DNA repair pathways. The unmodified PCNA is 
involved in normal replication. When replication stalls due to damage, PCNA is 
monoubiquitinated by Rad6/Rad18 to accomplish translesion synthesis. Polyubiquitination of 
PCNA involves Rad5/Ubc13 and MMS in addition to Rad6/Rad18 and this leads to error-free 
bypass of the damage by template switch to the undamaged sister chromatid. 
Abbreviations: Ubi – ubiquitin; PCNA – proliferating cell nuclear antigen; PCNA(Ubi) – mono-
ubiquitinated PCNA; PCNA
(Ubi) n
 – poly-ubiquitinated PCNA 
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system to the DNA and TLS is carried out by PCNA
(ubi)
 that recruits the error-prone 
polymerases such as Polε and Polδ. 
The mechanism of TLS involves the PCNA
(ubi)
 possibly by multiple polymerase switching 
events which include a TLS polymerase that inserts a base opposite to the damage and 
subsequently another specific TLS polymerase that extends the insertion by few additional 
nucleotides past the lesion (Friedberg et al. 2005). The interaction of PCNA
(ubi)
 and Polε has 
already been demonstrated (Kannouche et al. 2004; Watanabe et al. 2004). Polε is able to first 
insert a base independently of the information on the template strand (Johnson et al. 1999). 
The extension of the inserted base is performed by another polymerase such as Polδ encoded 
by REV3 and REV7 (Nelson et al. 1996), which is able to extend the insertion only for a few 
base pairs further owing to its low processivity. Similarly Polκ, another member of the TLS 
polymerases, is efficient in the insertion of the correct cytidine opposite of a benzo(a)pyrene 
adducted guanine base and is recruited by Rad18 to PCNA
(ubi) 
(Ohmori et al. 2004). Thus 
depending on the type of lesion many TLS polymerases are involved that are able to 
synthesize DNA past a lesion with low fidelity. 
2.7.2. Error free bypass 
In addition to Rad6 and Rad18, polyubiquitination of PCNA requires another ubiquitin 
conjugating heterodimer, Ubc13-Mms2 (Hofmann and Pickart 1999) recruited by the E3 
ubiquitin ligase – Rad5 (Ulrich and Jentsch 2000). The Ubc13-Mms2 and Rad5 cooperate 
with the Rad6-Rad18 heterodimer to generate polyubiquitinated PCNA (PCNA
(ubi)n
) using 
K63 linked polyubiquitin chains and activate the error-free template switch that is important 
for the completion of replication during replication stress (Broomfield et al. 1998; Hofmann 
and Pickart 1999; Ulrich and Jentsch 2000; Hoege et al. 2002; Branzei et al. 2004). The 
proteins modified with K63 polyubiquitin chains are involved in many cellular processes 
including DNA repair and are different from those modified with K48 linked ubiquitin chains 
that are subject to proteosomal degradation (Hofmann and Pickart 1999). 
The mechanism of activation of the error free bypass by PCNA
(ubi)n
 remains speculative. 
The template switch to the undamaged sister chromatid may be achieved by fork regression 
resulting in the formation of a four-way junction intermediate called “chicken foot” structure. 
This requires the unwinding of the leading and lagging strands of the replication fork and 
Rad5 is able to fulfill this requirement by its helicase activity (Blastyak et al. 2007). The DNA 
synthesis then occurs based on the information on the undamaged sister chromatid, thus 
achieving error-free bypass of the lesion. 
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2.7.3. Interactions of components of the Rad6 pathway 
The components of the Rad6 pathway and their interactions are highly conserved and the 
vertebrate homologs for all the known components of the Rad6 pathway have already been 
identified. In fact two proteins have been identified as the vertebrate homologues of Rad5, 
namely SHPRH and HLTF (Motegi et al. 2006; Unk et al. 2006; Motegi et al. 2008; Unk et al. 
2008). 
The interaction complexes of the Rad6 pathway have been described in yeast. There is 
substantial evidence for the assembly of two distinct UBC complexes mediated by Rad18 and 
Rad5, each for the error-prone and error-free pathways (Ulrich and Jentsch 2000). The 
homodimeric self association of Rad18 promotes the assembly of Rad6 to the complex that is 
involved in TLS, while the heteromeric association of Rad18 with Rad5 results in two distinct 
UBCs – Rad6 and Ubc13/Mms2 which activate the error-free bypass. It is postulated that the 
homodimerization and heterodimerization complexes are mutually exclusive and may not 
form supramolecular complexes owing to the weak interactions between Rad18, Rad5 and 
Ubc13 (Ulrich and Jentsch 2000). 
2.8. Molecular interplay between the Rad6 pathway and checkpoint 
signalling components 
There are evidences that indicate an important role of the Rad6 pathway in other signaling 
pathways affecting cell cycle, DNA repair and apoptosis. For instance, there are molecular 
crosstalks between components of the checkpoint signaling and the Rad6 pathway, resulting 
in the regulation of both pathways. 
The ssDNA binding protein - Replication Protein A (RPA) plays a central role in 
recruiting DNA repair proteins to the DNA damage. Recently, the direct interaction of RPA 
and Rad18 and the function of the RPA complex to recruit Rad18 to ssDNA in vitro was 
demonstrated (Davies et al. 2008). The recruitment of the Rad18-Rad6 complex to stalled 
replication forks by the ability of this complex to recognize forked and ssDNA structures is 
also known (Tsuji et al. 2008). Taking these two findings together, it may be postulated that 
the Rad18/Rad6 complex is able to recognize the damage and it is recruited to the DNA by 
RPA. Further, RPA is indeed known to be required for efficient PCNA ubiquitination (Davies 
et al. 2008). 
On the other hand, the ATR-ATRIP kinase complex and the 9-1-1 checkpoint clamp are 
also recruited separately to single-stranded (ss)DNA, by the interactions of ATRIP and the 9-
1-1 specific clamp-loader with the RPA complex (Zou and Elledge 2003; Zou et al. 2003). 
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These two complexes are activated by stalled replication forks, resulting in the initiation of 
the checkpoint signaling cascade during S-phase. 
A clear role of checkpoint signaling in the regulation of the Rad6 pathway has also been 
observed. The inhibition of RPA/ATR-Chk1 mediated S-phase checkpoint signaling partially 
inhibited PCNA ubiquitination and also prevented interactions between PCNA and Polκ (Bi et 
al. 2006). Another study revealed that while the ATR-Chk1 pathway is important for coping 
with intrinsic replication stress, Chk1 together with Claspin and Timeless regulate efficient 
ubiquitination of PCNA independently of ATR (Yang et al. 2008). 
While the influence of checkpoint signaling components on the Rad6 pathway is known, 
there is also recent evidence of the role of Rad6 pathway and/or its components on checkpoint 
signaling itself. For instance, in addition to ubiquitination of PCNA, the Rad6-Rad18 complex 
is also involved in the ubiquitination of the Rad17 (Rad1 in mammals) subunit of the 9-1-1 
checkpoint DNA clamp, thus promoting DNA damage-dependent transcriptional induction 
and checkpoint functions (Fu et al. 2008). The 9-1-1 DNA clamp is also known to be required 
for Ig gene conversion (Saberi et al. 2008). Although these data indicate a definite molecular 
crosstalk between the DNA damage response signaling components and the Rad6 pathway, 
the biological consequences of this communication are worth further study. 
2.9. Other functions of components of the Rad6 pathway 
Besides the role of the Rad6 pathway in DNA repair, Ig diversification and its interplay 
with the checkpoint signaling, the enzymes of this pathway are able to function with other 
unconventional substrates, or are themselves substrates to enzymes not involved in the 
pathway. For instance, there is evidence for an alternative PCNA ubiquitinating enzyme in 
DT40 (Szuts et al. 2006) and recently the E3 ligase RNF8 was found to be able to ubiquitinate 
PCNA, although the E2 conjugating enzyme involved in this reaction is yet to be identified 
(Zhang et al. 2008). Similarly, a Rad18 function independent of PCNA monoubiquitination 
has also been identified in S-phase specific SSB repair (Shiomi et al. 2007). Rad18 is also 
involved in HR in DT40 cells (Szuts et al. 2006) and plays a role in meiosis and sperm 
maintenance (van der Laan et al. 2004). Ubc13-Mms2 also interacts with the heterodimeric 
RING E3 BRCA1-BARD1 to polyubiquitinate BRCA1 (Christensen et al. 2007). Ubc13 is 
the only known E2 conjugating enzyme that performs K63 linkage of Ubiquitins. Rad6 is not 
only involved in DNA repair via the Rad6 pathway, but also in sporulation (Cox and Parry 
1968), retrotransposition (Picologlou et al. 1990), silencing (Huang et al. 1997) and in protein 
degradation (Sung et al. 1990; Dohmen et al. 1991). 
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2.10. Functional characterisation of Rad18 protein domains 
The components of Rad6 pathway are involved in many cellular processes besides their 
role in DNA repair at the stalled replication forks. Therefore it would be interesting to study 
the molecular interaction network of Rad18, the critical component of the Rad6 pathway that 
is involved in many other cellular processes. Rad18 exists in association with Rad6 and is 
usually present as a dimer of the Rad6/Rad18 heterodimer (Ulrich and Jentsch 2000; Miyase 
et al. 2005; Notenboom et al. 2007). The functional domains of Rad18 have been well 
characterized. Figure 6 shows a schematic representation of the functional domains of Rad18 
according to Notenboom et al. 2007. 
Rad18 is a multidomain E3 ligase, equipped with functional domains for DNA binding, 
PCNA modification and for interaction with Rad6, PCNA and Polε. At the N-terminus, 
Rad18 carries a RING domain (25 – 63 amino acid residues) that interacts with its cognate E2 
enzyme, Rad6. A second region between 340 – 395 residues in the C-terminus are also 
involved in this interaction (Bailly et al. 1997; Ulrich and Jentsch 2000; Back et al. 2002). 
The amino acid residues 401 – 445 in the C-terminus is also involved in binding to Polε 
(Watanabe et al. 2004). The C2HC Zinc-finger (ZnF) domain (201 – 255) was initially 
postulated to have a DNA binding potential (Jones et al. 1988; Bailly et al. 1994). Mutations 
of this domain disrupted self-association of Rad18, indicating that this potential DNA binding 
domain is essential for dimerisation (Tateishi et al. 2000; Ulrich and Jentsch 2000; Miyase et 
al. 2005). The ZnF domain is also important for auto-monoubiquitination and localisation of 
Rad18 to cyclobutane pyrimidine dimer damages of DNA (Nakajima et al. 2006), but in a 
later study it was found to be the binding domain for ubiquitin and rather not involved in 
DNA recognition (Notenboom et al. 2007). The SAP domain (248 – 282 residues), named 
after the three proteins in which the domain was first identified as a DNA interacting domain 
(Aravind and Koonin 2000), is capable of DNA recognition in vitro (Notenboom et al. 2007) 
and was also found to be responsible for the localisation of Rad18 to DNA foci containing 
Polε (Nakajima et al. 2006). 
While evidences for the role of Rad6 pathway in Ig gene diversification and its interplay 
with DNA damage checkpoint signaling are mounting, there are also substantial findings 
about the influence of other processes on regulation of the different events of the Rad6 
pathway. At this juncture, a robust biochemical and genetic approach is needed to unravel the 
hidden links of this crosstalk among different pathways to provide a more integrated 
perspective to the molecular network of the Rad6 pathway. 
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2.11. Biochemical and genetic approaches to study cellular networks 
The recent sequencing of the genomes of many organisms has steered reverse genetic 
approaches into a major focus of investigation. The study of cellular networks is important to 
understand the higher order molecular organization of cellular processes. Protein-protein 
interactions are intrinsic to cellular networks. There are many techniques to study protein 
interactions such as immunoprecipitation, affinity chromatography, library-based methods 
like the two-hybrid system and phage display, mutational analysis etc. The isolation and 
characterization of the complexes of the protein of interest followed by analysis of its 
Figure 6: Schematic representation of the functional domains and ligand-interacting regions of 
human Rad18 Source: Notenboom et al. 2007. The N terminus of the human Rad18 protein 
contains the RING domain (25-63) which along with the Rad6 binding domain (340-395) is 
essential for Rad6 interaction. The Zinc finger domain (201-225 residues) binds Ubiquitin while 
the SAP domain (243-282 residues) is required for DNA binding. Between 401-445 residues is the 
Polη binding region. The PCNA-interacting region that is contained within residues 16–366 
(shaded). K161, K261, K309 and K318 are four sites of autoubiquitination of Rad18 which are 
conserved between murine and human Rad18. The ubiquitination sites of the protein are also 
conserved in chicken Rad18 protein except the K161 site of ubiquitination. 
Abbreviations: Ubi – ubiquitin; PCNA – proliferating cell nuclear antigen; K – Lysine residue; 
Pol – Polymerase 
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constituents is one of the best approaches to study protein interactions. This would provide a 
better understanding of cellular networks than identifying one to one interactions, since 
proteins are often involved in more than one process or pathway that may or may not be 
interlinked. 
The information about protein interaction alone is not sufficient unless the functional 
significance of the interaction is elucidated. Protein interactions can have many different 
measurable effects on the level of its function (for a review see Phizicky and Fields 1995). 
One such measurable effect is in terms of alterations in the kinetic properties of the interacting 
proteins by altered catalysis, binding of substrates or allosteric properties of the complex. For 
instance, the ubiquitination status of PCNA alters its binding to different types of 
polymerases, while the binding also alters the processivity of a polymerase such as that of 
Polδ (Prelich et al. 1987). The other measurable effects of protein interactions are that the 
interaction may lead to new binding sites, allow for substrate channeling, inactivate or 
activate one of the interactors, and/or change the specificity of the protein for its substrate 
(Phizicky and Fields 1995). Thus, the functional analysis of different interactions is crucial to 
understand the impact of an interaction on cellular processes and ultimately interaction 
networks. Functional analysis can be carried out by analyzing the effects of genetic 
manipulation such as gene knockout or knockdown approaches, overexpression, silencing, etc 
and complementation of the phenotype. A combination of interaction studies and functional 
studies is therefore important to unravel cellular networks. 
2.11.1. The tandem affinity purification (TAP) technique 
While many methods of isolation of protein complexes are available, tandem affinity 
purification (TAP) is one of the few techniques that allows isolation of native protein 
complexes in even the lowest concentrations of protein complexes recovered (Rigaut et al. 
1999). The method does not require prior knowledge of the complex composition or function. 
In this method, the TAP tag is fused to the target protein of interest and expressed in the cell. 
The figure 7a represents the C-terminal and N-terminal TAP fusion constructs of a gene of 
interest (GOI). The TAP tag consists of two Ig binding proteinA domains of Staphylococcus 
aureus and a calmodulin binding peptide (CBP) separated by a Tobacco Etch Virus (TEV) 
protease cleavage site. The basic principle of TAP method is depicted in Figure 7B. The total 
cell extracts prepared from cells expressing the TAP tagged protein undergo two specific 
affinity purification/elution steps to recover the fusion protein along with its interaction 
partners. In the first affinity purification step, the Prot A binds tightly to an IgG matrix, 
requiring the use of the TEV protease to elute the bound material under native conditions. 
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Figure 7: A) Schematic representation of the TAP Tag: The TAP tag consists of Protein-A 
moiety, TEV site and CBP fused to the protein either to its C- or N- terminus. 
B) An overview of Tandem Affinity Purification (TAP): The TAP method involves two successive 
affinity purification steps. The first step exploits the tight binding of the Protein A moiety of the tag 
to IgG beads while the contaminants are removed with the supernatant. The bound protein is 
eluted by TEV protease cleavage. In the second purification step, the CBP of the TAP tag binds to 
the calmodulin coated beads in the presence of calcium ions. After removal of the contaminants 
with the flow-through, the complex is eluted in the presence of EGTA. 
Abbreviations: GOI – gene of interest; TEV – Tobacco Etch Virus; CBP – calmodulin binding 
peptide; CTAP/NTAP – C- or N- terminal TAP fusion; TAP – tandem affinity purification 
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In the second step, this eluate is incubated with calmodulin-coated beads in the presence 
of calcium. After washing away the contaminants and remnant TEV protease, the bound 
material is released under mild conditions with EGTA. For characterization of the protein 
complex thus recovered, the final eluate is concentrated before further analysis. 
2.11.2. The DT40 system 
The TAP tag is large (about 200 amino acid residues), so its fusion to the GOI may impair 
protein function and interactions. Consequently as a functional test, complementation of a 
knockout phenotype is an appropriate method to overcome this difficulty. The DT40 chicken 
B-cell line is an appropriate model system that allows easy manipulation of the genome in 
order to perform reverse genetic experiments and complementation studies. The cell line, 
derived from an avian leukosis virus (ALV)- transformed cells, is known for the ease of 
genetic manipulation for gene disruption experiments (Winding and Berchtold 2001) and it 
offers targeted to random DNA integration ratio far exceeding that of any mammalian cell 
line (Buerstedde and Takeda 1991; Winding and Berchtold 2001; Hudson et al. 2002). The 
Cre/loxP vector system is an ideal system to execute complementation of a knockout 
phenotype. While the disruption of multiple genes and complementation of phenotypes is 
limited by the number of available selectable markers, the recent development of mutant loxP 
vectors for conditional knockouts and selectable marker recycling in DT40 overcomes this 
limitation (Arakawa et al. 2001). 
The combination of the TAP method with the DT40 system offers the possibility to assess 
the functionality of the fusion in the knockout cells and also the competition for interaction 
partners between the endogenous protein and the TAP tagged fusion protein could be avoided. 
Functional studies can also be performed directly in cells deficient for the GOI or a novel 
interaction partner. Thus the combination of the DT40 knockout approach with the TAP 
technique constitutes an immensely powerful tool to study protein interaction networks and to 
identify and characterize new interaction partners for the protein of interest. Ig gene 
conversion and SHM are constitutive in this cell line (Sale 2004) and hence the study of 
factors regulating these Ig diversification processes is also feasible in this cell line. 
2.12. Objectives 
Rad18 appears to be a central player in regulating the Rad6 pathway; Ig gene 
diversification processes and DNA damage checkpoint signaling. There are also evidences of 
the regulation of the Rad6 pathway by the components of the checkpoint signaling system. 
Ultimately, the function of Rad18 in DNA damage repair outside the Rad6 pathway is also 
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known. All these facts taken together suggests a role of Rad18 as a global mediator in DNA 
damage recognition, response, repair affecting genome maintenance as well as adaptive DNA 
alterations during Ig gene diversification processes. 
Thus the aim of the current study was to identify new interaction partners of Rad18 which 
might lead to identification of 1) modulators of the Rad6 pathway, 2) factors that link the 
Rad6 pathway and SHM and possibly the mechanism of this interplay, and 3) factors linking 
the Rad6 pathway to other DNA repair pathways and/or cell cycle control. Following the 
identification of new interaction partners of Rad18, subsequent functional analysis for the new 
interactions would be performed if feasible, in order to achieve a better perspective on the 
Rad18 interaction network. 
Since the combination of high throughput proteomic analysis with a reverse genetic 
system has been well established in yeast, but not for vertebrate systems, the establishment of 
the TAP method in the DT40 cells would therefore be the first of its kind for such studies in a 
vertebrate system. The success of the TAP method in DT40 would be tested using AID-TAP 
fusion constructs already available, followed by mass spectrometric analysis of the 
constituents of the complex purified thereby. Subsequently, this approach would be adapted to 
study the Rad18 interaction network, thereby establishing a system that in future could be 
extended to study protein interaction network of any protein of interest. 
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3. Results 
The approach that was used to investigate the interaction network of the Protein of 
Interest (POI) in the DT40 chicken B cell line entailed the isolation of native complexes of the 
POI by the TAP method followed by mass spectrometric analysis (Figure 8). The GOI fused 
to the TAP tag comprising a protein A, TEV cleavage site and CBP was expressed in the GOI 
knockout DT40 cells and verified for functionality of the fusion. At expression levels 
comparable to the endogenous gene, the fusion interacts and forms complexes which were 
then purified by the TAP method. The proteins in the final eluates of this purification were 
concentrated and subjected to in-gel trypsin digestion. The mixture of peptides generated by 
the trypsin digest was resolved by nano-liquid chromatography (nano-LC) based on the 
hydrophobicity of each peptide. The nano-fractions eluting from the capillary of the LC 
system were mixed with the matrix, a-Cyano-4-hydroxycinnamic acid (CHCA), while being 
collected on a MALDI target by the automated Probot microfraction collector from Dionex 
Corporation. Subsequently, the peptide samples were subjected to mass spectrometric analysis 
by Matrix Assisted Laser Desorption Ionization/Time-of-flight (MALDI TOF/TOF) using the 
4700 proteomics analyser from Applied Biosystems Inc. The data from the MS/MS analysis 
were processed with the GPS Explorer software using the MASCOT search engine and the 
NCBI Gallus database to generate a list of potential interaction partners of the bait protein. 
The cell clone expressing the TAP tag alone was used as an appropriate negative control. This 
approach was established in DT40 cells in this study using the AID-TAP fusion as a model 
system, since an equivalent purification was already successfully accomplished in the Raji 
human B cell line (Tobollik 2007). The approach was then adapted for the study of the Rad18 
interaction network. Hence, the current study can be categorised into two parts, namely 1) the 
establishment of TAP in the DT40 cell line and 2) the study of the Rad18 interaction network 
in DT40 cells. 
3.1. Establishment of TAP in the DT40 cell line using AID-TAP fusions 
The AID-TAP tagged constructs were already available with the TAP tag fused to the 
human AID either at the C-terminus or at the N-terminus of the protein, designated as AID-
CTAP and NTAP-AID, respectively. The functionality of the AID-TAP fusions was 
ascertained earlier and it was known that the AID-CTAP fusion was functional for SHM 
whereas the NTAP-AID fusion was non-functional (Tobollik 2007). 
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3.1.1. Expression of the AID-TAP fusion proteins in the DT40 cell line 
There are two alternatives to express the TAP tagged fusion protein. One is to express 
the fusion from the endogenous locus by modifying the C-terminal or the N-terminal exons. 
The other option is to stably transfect exogenous vectors carrying the fusion protein with a 
suitable promoter into the GOI knockout DT40 cells. The NTAP-AID fusion in the pCAG 
vector and the AID-CTAP fusion in the pZome as well as a pCAG vector were readily 
available. Hence the exogenous expression of the TAP fusion was tested. The general features 
of the two vectors are depicted in Figure 9. 
The 141pCAG-3SIP vector carries a composite CAG promoter that combines the human 
cytomegalovirus immediate-early enhancer (hCMVieE) and a modified chicken beta-actin 
promoter (Niwa et al. 1991). The CAG is known to drive a very strong expression of the 
downstream transgenes. The puromycin resistance gene is expressed from an 
Encephalomyocarditis internal ribosomal entry site (EMC IRES) element that is placed 3‟ of 
the GOI so that both the resistance gene and the GOI are driven by the CAG promoter. The 
pZome-1C vector is based on pBABE that carries Long Terminal Repeats (LTRs) to drive the 
expression of the fusion and a Simian Virus 40 (SV40) promoter to express the puromycin 
resistance gene. The vector is supplied by the company Cellzome, Heidelberg, Germany and 
was the original TAP tag vector. 
Figure 8: An overview of the approach to study protein interaction networks in DT40 cells. See 
text for details.  
Abbreviations: GOI-TAP – TAP tagged gene of interest; GOI-/- – knockout of gene of interest; 
MALDI – Matrix assisted LASER desorption ionisation; TOF – Time of flight 
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The differences in the type of promoters, in the number of copies transfected per cell 
and in the site(s) of integration into the genome may result in clones with a wide range of 
exogenous expression levels. This allows the choice of the clone with an optimum expression 
level that is required for a successful proteomic approach and that is closest to the endogenous 
expression level. 
The expression of the endogenous GOI and the exogenous TAP fusions from the 
expression vectors were assessed by quantitative Reverse Transcriptase - Polymerase Chain 
Reaction (qRT-PCR) and Western blotting for the mRNA and protein amounts, respectively. 
The estimation of the cDNA quantity was performed in a Light Cycler
®
 by the Syber Green
®
 
method. The relative number of mRNA copies was estimated by normalising to the reference 
gene, Hypoxanthine phosphoribosyltransferase (hprt), which should be expressed 
constitutively on an identical level in all samples analysed. The relative amounts of mRNA 
for the endogenous GOI and its exogenous GOI-TAP fusions are summarised in Table1. 
Figure 9: A Schematic depiction of the exogenous expression vectors tested: pZome-1C carrying 
a LTR promoter and SV40 driven puromycin resistance and pCAG-3SIP with a CAG promoter 
and puromycin resistance gene. The constructs were cloned in such a way that the PCR amplified 
GOI was cloned into the BamHI site. The GOI-TAP insert in this vector was then cleaved out 
using the EcoRI enzyme and cloned in to the pCAG-3SIP vector. The AID-TAP contructs were 
already available in these vectors from an earlier study (Tobollik 2007). 
Abbreviations: LTR – long terminal repeats; SVp – Simian Virus promoter; puro – puromycin 
resistance; ampR – ampicillin resistance; CBP – calmodulin binding peptide; TEV – tobacco etch 
virus protease cleavage site; SV40 – Simian virus 40 promoter; py ori – Polyoma origin of 
replication; hCMVieE – human cytomegalovirus immediate-early enhancer; EMC IRES – 
Encephalomyocarditis internal ribosomal entry site 
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The endogenous mRNA levels of AID and Rad18 were estimated to be 1.89 mRNA 
copies per hprt copy and 1.2 mRNA copies per hprt copy, respectively. For exogenous 
expression of AID-TAP fusions, the pZome and pCAG vectors carrying the AID-TAP fusions 
were stably transfected into AID
-/-
 DT40 cells. The pCAG expressing AID-CTAP fusion did 
not yield any transfected clones even upon repeated attempts, whereas the transfection of 
pCAG expressing the NTAP-AID fusion and the pZome expressing the CTAP-AID fusion 
were successful. A reason for this might be that the functional AID-CTAP fusion, when 
expressed from a potential overexpression vector such as pCAG, could result in too high 
mutagenesis for the transfected DT40 cells to survive. 
The mRNA levels of the AID-CTAP fusion expressed from the pZome vector were 
between 0.26 to 13.2 mRNA copies per hprt copy, i.e. ranging from nearly physiological 
expression levels to slight overexpression (Figure 10A). The pCAG vector expressed the 
NTAP-AID fusion at a much higher level, ranging from 79.09 to 360.13 mRNA copies per 
hprt copy (Figure 10A). Hence, this vector could serve as an overexpression vector if 
required. 
The protein levels were determined by western blot analysis and were compared to the 
fusion protein amounts expressed in the human cell line Raji, which were already known to be 
sufficient for a successful TAP purification (Figure 10B). It was deduced that a protein level 
Table 1: An overview of exogenous and endogenous expression levels determined by qRT-PCR.. 
The mRNA was isolated from the cells and reverse transcribed. The cDNA thus obtained was used 
to assess the relative copy numbers of the exogenous AID-TAP fusions and the endogenous GOIs 
with respect to hprt as the house keeping gene. The qRT-PCR was performed in the Light Cycler by 
the Syber Green
®
 method. The exogenous vectors pZome and pCAG controlled the gene expression 
from the LTR and CAG promoters, respectively. This was compared to the expression levels 
achieved by the endogenous promoters of the GOIs. 
Abbreviations: AID – Activation Induced Cytidine deaminase; LTR – Long terminal repeats; CAG 
– the CAG promoter; HPRT – Hypoxanthine phosphoribosyltransferase; GOI – gene of interest 
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corresponding to 5 to 10 copies of fusion protein mRNA per hprt copy should be sufficient to 
make a successful TAP procedure. The clone number 1B of the AID-CTAP clones with 5.62 
mRNA copies per hprt copy and clone number 3B of the NTAP-AID clones with 360.13 
mRNA copies per hprt copy were selected as representative of close to physiological and 
overexpression clones for further experiments. AID-CTAP fusion and TAPalone clones 
generated in ψ- AID-/- cells (pST10-10B and pSK1-1A, respectively) were also used in the 
establishment of the approach. 
Figure 10: Expression levels of AID-TAP fusions in DT40 cells. 
A) qRT-PCR data for AID-TAP mRNA expression normalised to hprt expression. Values derived 
from AID-CTAP expressed from pZome are given in blue while those derived from AID-NTAP 
expressed from pCAG are given in grey. The mean and standard deviation of two independent 
quantifications are indicated. 
B) Western blot analysis of AID-TAP expression. The fusion proteins were detected with a 
peroxidase antiperoxidase (PAP) reagent detecting the TAP tag. The DT40 clones expressing the 
AID-TAP fusions were loaded along with AID-TAP expressing human Raji clones that were 
previously used for a successful TAP method. The last lane shows the highest expression of AID-
CTAP that was achieved in Raji cell line. Ponceau S staining is shown as a control of equal 
loading. 
Abbreviations: AID – activation induced cytidine deaminase; hprt - Hypoxanthine 
phosphoribosyltransferase 
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3.1.2. Tandem affinity purification in DT40 cells using the AID-TAP fusions 
Whole cell protein extracts were made from 5x10
8
 cells of CTAP- and NTAP-AID 
expressing clones. The pCAG vector expressing the TAP tag alone in DT40 cells (henceforth 
referred to as “TAPalone”) served as an appropriate negative control. The extract was then 
subjected to TAP during which the fusion protein underwent two specific affinity purification 
steps to recover the bait protein along with its interaction partners. The technique will be 
described in detail in the methods (section: 5.2.7). 1/10th of the input and fractions of each 
step of the purification were collected for western blot and silver stain analyses. The aliquots 
of the calmodulin beads (CB) flow through and CB eluate were concentrated by 
Trichloroacetic acid (TCA) precipitation before performing further analysis. 
3.1.2.1. Western blot analysis of the TAP fractions in DT40 cells 
The western blot of the TAP was analysed with the anti-AID (5G9) antibody for the 
purification of the AID-TAP fusions (Figure 11a). The 1
st
, 2
nd
 and the 3
rd
 lanes were loaded 
with 1/1600
th
 of the original volume of the whole cell protein extract (input), IgG beads 
supernatant and IgB before TEV cleavage, respectively. These three lanes represent the 
success of IgG binding of the fusion proteins to the beads. This step was successful with a 
variation of 50% to 90% binding in different experiments. 
The next three lanes were loaded with 1/80
th
 of the original volume of the IgG beads 
before TEV cleavage, IgG beads after TEV cleavage and the TEV eluate to analyse the 
efficiency of the TEV cleavage step. As expected, after TEV cleavage, the electrophoretic 
mobility of the AID-CBP protein was detected at a lower molecular weight of about 30kDa. 
This step was successful with a variability of 60% to 90% between different purification 
experiments and samples. The final recovery of the TEV-cleaved fusion in the TEV eluate 
was nearly 95-100%. 
The last three lanes represent the final steps of the TAP method, the calmodulin binding 
and elution steps. These lanes were loaded with 1/40
th
 of the original volume of the CB Flow 
through, CB-E and the calmodulin binding beads after elution. The western blot analysis 
showed that detectable amounts of the fusion protein were recovered in the final eluate, 
although a substantial amount of the fusion was lost in the flow through and some of the 
fusion remained bound to the beads. The amount of protein finally eluted was about 3-5% of 
the amount contained in the TEV eluate. The range of loss and recovery of the fusion protein 
in the different steps of the purification was within the known experimental feasibility of the 
method (Rigaut et al. 1999). 
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Figure 11: Analysis of tandem affinity purifications of AID-TAP fusions. 
A) Western blot analysis of tandem affinity purifications of NTAP-AID (Tf2/3B) and AID-CTAP 
(pST10-10B) fusions and TAPalone (pSK1-1A). The Ig binding (lanes 1 to 3), the TEV protease 
cleavage step (lanes 4 to 6) and the calmodulin binding and elution (lanes 7 to 9) are shown. The 
fusions were detected with anti-AID (5G9) antibody and the TAPalone control was detected with 
PAP reagent. 
B) Copurification of Replication protein A (RPA). The CB-E of the AID-CTAP (Tf5/1-1B) shows 
copurification of RPA while the TAPalone control lost the RPA in the CB F.T. 
C) Silver-stain analysis of the TAP purification for AID-TAP fusions, Tf2/3B, pST10-10B and 
TAPalone, pSK1-1A. Specific bands for the fusions and protein depletion could be seen. The 
fraction of the volume of sample at each step that was loaded in the gel is shown in  parentheses. 
Abbreviations: IgB Supt. – Ig beads Supernatant; IgB before TEV – Ig beads before TEV; IgB 
after TEV – Ig beads after TEV protease cleavage ; TEV E – TEV protease eluate; CB F.T. – 
Calmodulin binding flow through; CB E – calmodulin binding eluate; CB B – calmodulin binding 
beads 
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The TAPalone control used in the purification was analysed with peroxidase anti-
peroxidase (PAP) reagent that detects the protein A moeity of the TAP tag. Since the protein 
A is cleaved off after the TEV cleavage step, the western blot analysis for the TAP alone 
could be assessed only for the Ig binding step. 
The co-purification of a known AID interaction partner, RPA (Chaudhuri et al. 2004), 
along with the bait protein in the final step of the TAP purification was verified by western 
blot analysis. Figure 11B shows the co-purification of RPA in the final eluate of the AID-
CTAP fusion, while it was lost in the CB flow through for the TAPalone, indicating the 
importance of the second step of the TAP purification. It was not possible to verify the same 
for the NTAP fusion since the mobility of the CBP-AID cleaved from the NTAP fusion was 
the same as that of RPA on the SDS PAGE. 
3.1.2.2. Silver Stain Analysis of the TAP fractions 
A silver staining of the different fractions of the TAP purification showed that there was 
depletion of many nonspecific proteins throughout the purification (Figure 11C). Also, there 
were some bands that may indicate potential interacting proteins of AID for the AID-TAP 
fusions and not for the TAPalone (Figure 11C). The final eluate of the TAP purification 
contained a mixture of proteins enriched for the proteins of the complexes formed by the bait 
protein. The proteins that were present owing to contamination were expected to be 
comparable to the background obtained in the TAPalone. The sensitivity of detection by the 
silver stain for smaller proteins is lower because there are fewer amino acids for the binding 
of the Ag
+
 ions. Due to this reason, the detection of very low amounts of smaller proteins in 
the final eluate was borderline or nearly absent. 
From the western blot and silver stain analysis, it was concluded that the TAP 
purification was feasible in the DT40 system with protein amounts expressed corresponding 
to 5-10 copies of mRNA per hprt. The final eluates obtained from the purification were 
concentrated by TCA precipitation to carry out in-gel tryptic digestion. 
3.1.3. Trypsin Digestion and nano-Liquid Chromatography of the final 
eluates 
The final eluates of the TAP purification were trypsinised by an in-gel method. The 
resulting peptides were eluted out of the gel, lyophilised and finally dissolved in 0.1% 
Trifluroacetic acid (TFA). Each final eluate of a given sample was split into two fractions at 
this point and processed further as two separate LC/MALDI experiments. The dissolved 
peptides of each fraction of a sample were purified and separated by reverse phase nano-LC 
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based on the hydrophobicity of the peptides. During this separation, the UV detector 
generated an output in form of peaks representing the quantity and number of different 
peptides in the sample. Figure 12 shows a liquid chromatography profile of the AID-CTAP 
and NTAP fusions compared to the TAPalone. 
The separated peptides eluting out of the LC unit were loaded on a MALDI target along 
with the CHCA matrix by the probot microfraction collecter from Dionex. The samples were 
spotted such that a total of 275 spots were loaded for each sample. The target was then loaded 
onto the 4700 proteomics analyser from Applied Biosystems for MALDI TOF-TOF analysis, 
during which each spot was identified by the analyser by its retention time. 
The CTAP fusion protein samples had specific peptide peaks that were not present in the 
TAPalone (Figure 12A) while NTAP fusions of all purifications showed nearly no significant 
peptide peaks compared to the TAP alone (Figure 12B). 
Figure 12: The chromatogram of the nano-LC separation of AID-TAP fusion peptides. The 
chromatogram of the peptides of A) AID-CTAP (blue) vs. TAPalone (black) and B) NTAP-AID 
(blue) vs. TAPalone (black) are shown. The intensity of the peptide peaks are expressed in 
absorbance units (mAU) and plotted against the retention time (in mins). 
Abbreviations: mAU – milli absorbance units; AID – activation induced cytidine deaminase 
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3.1.4. MALDI TOF-TOF analysis of the peptides of the AID fusion eluates 
During the MALDI analysis, the peptides were ionised by a LASER beam and were 
accelerated across the vaccum chamber with varying velocities according to the mass/charge 
ratio of the peptides. The peptides were identified by a detector that extrapolated the mass of 
the peptides based on the time of flight (TOF) compared to that of a known standard. The 
peptides thus identified were more for the AID-CTAP and NTAP fusion samples than for the 
TAPalone. For instance, in the same experiment of the LC profile shown in Figure 12A, there 
were 872 and 579 unique peptides identified for the AID-CTAP and TAPalone samples, 
respectively. The 4700 proteomic analyser is also capable of MS/MS optics that was used to 
identify these peptides with higher accuracy. During the MS/MS optics, the peptide ions 
previously identified during the MS optics were selected. These peptides were subjected to 
high energy collision induced dissociation (CID) by activation of the peptide ions after 
collisions with a gas. These high energy collisions result in fragmentation of the peptide into 
smaller fragments of lower masses. These additional fragmentation patterns of the peptides 
generated a raw MS/MS data of the individual peptides identified by the MS optics. 
3.1.5. Generation of an NCBI Gallus database and MASCOT analysis for 
AID-TAP fusions 
The data generated by the MALDI TOF-TOF optics were processed by the MASCOT 
software. The MASCOT search algorithm is based on the Mowse scoring algorithm that has 
been described earlier (Pappin et al. 1993) combined with a probability based scoring. This 
software is able to assign an ion score for each peptide based on the significance and 
reliability of the match between a peptide and a protein sequence in the database. The ion 
scores were added together for the identification of a protein which had the best peptide 
coverage. The total ion scores thus calculated were used to generate a list of proteins arranged 
in the order of significance that represented the proteins that may be present in the samples 
analysed. 
Many of the chicken proteins are not sufficiently conserved with the other taxonomic 
groups. In order to assess which protein database served as the most optimal database to 
analyse the MALDI data, the MASCOT analysis was done with three different databases, 
namely Swissprot, NCBI (entire), and NCBI Gallus databases. 
The NCBI Gallus database was downloaded especially for this study from the NCBI 
website by the following procedure. All proteins entries with a “Gallus” search tag were 
displayed in FASTA format in the NCBI website, resulting in 36,215 entries as on the date of 
creating the database. The sequences were then exported to the clipboard by using the <send 
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to> function in the webpage and pasted into a text file. The text file with all the sequences 
was saved and then set up in the MASCOT software search engine as per the instructions 
given on the Matrix Science company webpage for setting up a database in the MASCOT 
server (http://www.matrixscience.com/help/seq_db_setup.html). The database is frequently 
updated for new protein sequence entries and the latest sequences of existing entries. 
The original lists for the AID fusions generated with the analyses using all three 
databases are provided in the Appendix 1. The use of the NCBI Gallus database for the 
MASCOT search analysis yielded the most optimal results, as there were significant scores 
for AID and the potential interaction partners previously identified in the analysis with the 
Raji human cell line (Tobollik 2007). The AID fusions generated more significant and unique 
proteins compared to the TAPalone. The results of the two fractions of a given sample were 
compiled into a single list of proteins. The TAPalone control also generated a list of proteins 
that may be considered the background contaminants which were substracted from the AID 
fusion lists. Table 2 shows a simplified overview of the proteins identified as potential 
interaction partners of AID, generated using the NCBI Gallus database. The original lists with 
more details are included in the Appendix 1. 
The bait protein AID was identified with a significant score. Although the bait protein is 
enriched in the fusion samples during TAP, only 1 to 2 peptides were identified for AID with 
the NCBI Gallus database, while the same data when analysed with the swissprot database 
could identify 4 to 5 peptides. This may be due to the fact that the AID cDNA in the TAP 
constructs used was that of the human protein sequence which shares only 89% homology 
with the chicken AID protein. 
The known and previously identified interaction partners of AID were also found in the 
MALDI analysis of the AID fusions. Tubulin, for instance, is a known interaction partner of 
AID and implicated as a potential cytoplasmic retention factor in the regulation of nuclear 
exclusion of AID (Wu et al. 2005). Although tubulin is often considered as a potential 
contaminating protein in MS analyses, it was found with a significant score for AID fusions 
with a better sequence coverage than in the TAPalone. For instance in the purification of 
CTAP-AID (pST10-10B), tubulin was identified with many peptides while in the TAPalone 
(pSK1-1A) it was found with only 2-3 peptides. In fact, in one purification (TAP3), tubulin 
was only identified in the fusion sample and not in the TAP alone. The Ubiquitin-protein 
Ligase EDD1 and Ubiquitin are implicated in the ubiquitin proteosome system and were 
previously identified in the proteomic analysis for AID interaction partners in Raji, a human B 
cell line (Tobollik 2007). These proteins were also identified with a significant score in the 
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AID fusion samples generated from the DT40 cell line. Besides these, there were also many 
other proteins identified which are categorized as “others” in the table 2. The relevance of 
these proteins to AID function was not evident and to investigate the functional link of AID 
with these proteins was beyond the scope of this project. Based on the fact that the bait 
protein AID and the previously identified proteins of the ubiquitin proteasome system were 
found in the MALDI analysis with a significant score, it could be concluded that the 
proteomic approach of TAP combined with MS analysis was successfully established in the 
DT40 cell line. The approach was then applied to study the Rad18 interaction network in 
DT40 cells. 
 
Proteins identified with significant score 
TAP Tagged Bait Protein Activation Induced Cytidine Deaminase 
Ubiquitin Proteosome system 
previously identified in a similar study in 
the human cell line – Raji (Tobollik 2007) 
Ubiquitin-protein Ligase EDD1 
Ubiquitin 
Potential cytoplasmic retention factor – 
known interaction (Wu et al. 2005) 
Tubulin 
Heat shock proteins HSP 90 alpha 
Others, such as … 
Proteasome activator complex subunit 3 
Dedicator of cytokinesis protein 7 
Rho guanine nucleotide exchange factor 3 
ADP/ATP translocase 2 
complement component 4 binding protein, alpha isoform 3 
DnaJ-class molecular chaperone with C-terminal Zinc 
finger domain 
PREDICTED: similar to pDJA1 chaperone 
Nuclear pore complex protein hnup153 
Downstream of kinase 3 protein 
galectin-3-binding protein-like (Tumor associated 
antigen 90K) 
PREDICTED: similar to ubiquitin-specific protease 
USP32 
Unknown Proteins 
Hypothetical protein – Unknown – gi|118107414 
Unknown (protein for MGC:160383) – gi|120538297 
Potential Contaminants Keratin 
Trypsin 
Calmodulin 
Actin 
 
 
Table 2: A compilation of some of the potential interactions identified for AID-TAP fusions when 
using the NCBI Gallus database for the MASCOT search analysis. The bait, known interaction 
partners and previously identified potential interactors are mentioned in the appropriate categories. 
The relevance of the other potential new interaction partners to AID function was not evident and a 
few of them are listed as “others” in this table selected as examples with no particular criterion for 
selection. The original lists with all the proteins are given in the appendix 1. 
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3.2. Study of the Rad18 interaction network in DT40 cells 
Since the TAP method was successfully established in DT40 cells using AID-TAP 
fusions, it was then adapted for analysing the Rad18 interaction network in the DT40 cell line. 
The chicken Rad18 protein shares only 48% homology with the human Rad18 and hence the 
antibodies available for the human protein did not crossreact with the chicken Rad18 protein. 
Therefore, in order to be able detect the fusion protein on western blots beyond the TEV 
cleavage step, it was necessary to add a HA tag in the cloning of the Rad18-TAP fusion 
protein. The pZome vector was used for expressing the fusion in rad18
-/-
 cells, in order to 
achieve close to physiological expression levels. 
3.2.1. Exogenous expression of Rad18-HA-TAP fusions in rad18
-/-
 DT40 cells 
The clones obtained by stable transfection of Rad18-HA-TAP constructs were analysed 
for the mRNA and protein levels of the fusions by qRT-PCR (Figure 13A) and western blot 
analysis (Figure 13B). 
 
 
 
 
Figure 13: Expression levels of Rad18-HA-TAP fusions 
A) qRT-PCR data for Rad18-HA-TAP mRNA expression normalised to hprt expression. The values 
derived from Rad18-HA-CTAP clones expressed from pZome vector are given in blue and those of 
the NTAP-HA-Rad18 are shown in grey. Mean and standard deviation derived from two 
quantifications are indicated. 
B) Western blot analysis of Rad18-HA-TAP fusions detected with anti-HA reagent. Ponceau S 
staining is shown as a control of equal loading. 
Abbreviations: hprt – Hypoxanthine phosphoribosyltransferase; HA – Hemagglutinin epitope 
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As observed earlier for the AID-TAP fusions, most of the clones showed a correlation of 
their mRNA and protein amounts. Expression ranges between 3.15 and 29.65 mRNA copies 
per HPRT were obtained for the Rad18-HA-CTAP fusions and between 0.45 and 11.3 mRNA 
copies per HPRT for the NTAP-HA-Rad18 fusions. The CTAP fusion clone number Tf9/1-1 
expressing 7.52 mRNA copies per HPRT and the NTAP fusion clone number Tf9/3-3 
expressing 11.3 mRNA copies per HPRT were chosen for further analysis. Since the 
TAPalone clones obtained in the rad18
-/-
 cells did not express the tag sufficiently for a 
successful TAP, these clones were not used as a negative control for the TAP method. The 
TAPalone clone generated in the wildtype DT40 cells, which was used earlier for the 
establishment of the technique, was used as the negative control for all the experiments except 
the cisplatin colony survival assay (which will be described in the section 3.2.4). The Rad18-
HA-TAP fusions were characterised for functionality, complex formation and nuclear 
localisation before they were used in TAP. 
3.2.2. Native PAGE of Rad18 fusion protein complexes 
The Rad18-TAP fusions were assessed for their ability to form complexes with other 
proteins in the cell as a large tag might affect the interaction of Rad18 with other proteins. 
The extracts of Rad18 fusion and TAPalone clones were subjected to native PAGE. 
Considering the known interaction partners of the complexes mediating TLS and error 
free bypass (Ulrich and Jentsch 2000), the potential size of such complexes were estimated for 
Rad18 fusions to be a minimum of 244kDa and 461kDa, respectively. The protein sizes of 
Rad6 and Rad18 were taken into account for calculating the potential complex for TLS while 
Rad5, Ubc13, Mms2, SHPRH and HTLF were also included to estimate the size of the 
complex that mediates error-free template switch bypass. The native PAGE revealed that 
Rad18 does form specific complexes of the size of about 720kDa or more while in the 
TAPalone this complex was absent (Figure 14A). The ponceau stain of NativeMark™ 
Unstained Protein Standard was used to make a rough estimated of the complex size. 
3.2.3. Cellular localization of Rad18 fusion proteins 
The Rad18 fusions were then characterised for their cellular localisation. For this, the 
clones expressing the fusions and the TAPalone were fractionated for their nuclear and 
cytoplasmic components and analysed by western blot. The quality of separation was assessed 
by analysing for GAPDH and p53 in the fractions. The GAPDH was not detectable in the 
nuclear fractions but only in the cytoplasmic fractions, implying that the nuclear fractions 
were pure. As a control that the nuclear fraction is not completely devoid of proteins, p53 
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protein was also detected predominantly in the nucleus. Thus it was concluded that the 
fractionation was successfully accomplished (Figure 14B). 
Subsequently, the localisation of the Rad18 fusions and the TAP tag alone was 
determined using the PAP reagent. It was observed that majority of the Rad18 fusions was 
detectable in the nuclear fraction where the known function of the protein is implicated. The 
TAPalone remained predominantly in the cytoplasm although some amount was also detected 
in the nuclear fraction. This may be due to passive diffusion since the protein is only 20kDa in 
size. The cellular localisation of the known Rad18 interaction partners such as Ubc13 and 
PCNA was also ascertained. Ubc13 was predominantly in the cytoplasm and at detectable 
levels in the nucleus. PCNA was detected in both the nuclear and cytoplasmic fractions. 
 
Figure 14: A) Native PAGE of Rad18 fusions and TAPalone. Native extracts of Rad18-HA-TAP 
fusions and TAPalone were subject to PAGE and probed with PAP reagent. The NativeMark™ 
Unstained Protein Standard was used in combination with PonceauS stain of the PVDF membrane 
to estimate the complex size. 
B) Nuclear/cytoplasmic localisation of Rad18-HA-TAP fusions and TAPalone control. GAPDH 
and p53 were analysed to assess the quality of separation of nuclear and cytoplasmic fractions. The 
localisation of the Rad18-HA-TAP fusions and TAPalone was analysed using the PAP reagent and 
the localisation pattern of known interaction partners, Ubc13 and PCNA were also verified with 
the appropriate reagents. 
Abbreviations: PAGE – Polyacrylamide gel electrophoresis; PAP – peroxidase antiperoxidase; 
PVDF - Polyvinylidene difluoride; GAPDH – Glyceraldehyde 3-phosphate dehydrogenase; PCNA 
– Proliferating cell nuclear antigen; T – Total extract; N – Nuclear fraction; C – cytoplasmic 
fraction 
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3.2.4. Functional Characterization of Rad18-HA-TAP fusions 
The rad18
-/-
 DT40 cells are known to be more sensitive to cisplatin than the wildtype 
cells (Yamashita et al. 2002). Hence the functionality of the fusions was analysed by 
assessing the survival of the clones upon DNA damage after treating the cells with different 
doses of cisplatin and plating them on methyl cellulose as described earlier (Simpson and Sale 
2006). In brief, 2x10
5
 cells of DT40 wild type, rad18
-/-
, Rad18-HA-CTAP clone, NTAP-HA-
Rad18, and rad18
-/-
 TAPalone were each treated with increasing doses of cisplatin for 1hour 
at 37°C. The cells were then plated on methyl cellulose media in 6 well plates and incubated 
at 37°C for 10 to 14 days. The same numbers of untreated cells were also plated as control. 
Colonies formed by the surviving cells were counted for all the doses and normalised to the 
number of colonies formed by untreated cells (0μM). The values were plotted on a graph as 
shown in the Figure 15. 
The results of this experiment were consistent with the known phenotype. The Rad18-
HA, –CTAP and –NTAP fusion expression in the rad18-/- cells restored the resistance to 
cisplatin to a similar level as in the wild type cells, while the TAPalone clone remained almost 
as sensitive as the rad18
-/-
 cells. The experiments were set up in triplicates for statistical 
significance and repeated for consistency. The results showed that the Rad18-HA-TAP 
fusions are as functional as the wild type protein in supporting survival of DNA damage. 
 
 
 
 
 
Figure 15: Survival curves of the methylcellulose colony survival assay with increasing doses of 
cisplatin (in μM). The rad18-/- and rad18-/-TAPalone cells showed sensitivity to increasing doses 
of cisplatin while the Rad18-HA-TAP fusions survived similar to the wildtype DT40 cells. The 
percentage survival at each dose was normalised to the untreated control. The experiment was set 
up in triplicates and the mean and standard deviation are also represented in the survival curves 
shown above. 
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3.2.5. Isolation of Rad18-HA-TAP fusion complexes by the TAP method 
The Rad18 fusions, thus characterized for expression, complex formation, cellular 
localisation and functionality, were then used to perform a TAP to isolate the complexes 
formed by the fusion protein. The TAP of Rad18 fusions was done as previously implemented 
for the AID fusions. The different fractions were collected and the purification was analysed 
by western blotting and silver stain analysis as previously shown for AID purifications. From 
the western blot analysis it was observed that the Ig binding was successful with a variability 
of 20% to 80% in different purifications and samples. The recovery of the TEV eluate and the 
calmodulin binding were nearly 95 - 100%. The final elution from the calmodulin beads 
worked with an efficiency of 5% to as much as 20% of the amount contained in the TEV 
eluate (Figure 16A). 
 
 
 
 
Figure 16: Western blot analysis of tandem affinity purification of Rad18-HA-TAP fusions 
A) The success of the TAP method of Rad18-HA-TAP fusions was analysed with anti-HA antibody. 
PAP reagent that detects the TAP tag was used for the TAP alone control. The fraction of the 
volume loaded to the total volume of each fraction is indicated. The Ig binding (lanes 1 to 3), the 
TEV protease cleavage step (lanes 4 to 6) and the calmodulin binding and elution (lanes 7 to 9) 
were shown to be successful. 
B) Co-purification of Rad6. The CB-E of the Rad18 fusions show copurification of Rad6 while the 
TAPalone control lost the Rad6 in the CB F.T. 
Abbreviations: IgB Supt. – Ig beads Supernatant; IgB vor TEV – Ig beads before TEV; IgB after 
TEV – Ig beads after TEV protease cleavage ; TEV E – TEV protease eluate; CB F.T. – Calmodulin 
binding flow through; CB E – calmodulin binding eluate; CB B – calmodulin binding beads 
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The TAP fractions of Rad18 fusions were also analysed for the copurification of a 
known interaction partner of Rad18. Rad6 is present in the Rad18 complexes involved in TLS 
as well as in the error-free bypass. Rad6 was co-purified with the Rad18 fusions but was lost 
in the CB flow through for the TAPalone control (Figure 16B), implying that the complexes 
were intact throughout the purification steps. 
3.2.6. Silver Stain analysis of the Rad18 TAP fractions 
A silver staining of the different TAP fractions showed that there was protein depletion 
throughout the purification. There were some specific bands for the NTAP fusion expressing 
clones and not for the TAPalone control while the CTAP showed detectable bands only when 
more protein was loaded. These results indicated that the purification was successful (Figure 
17). In the NTAP fusion sample, specific bands displaying a potential complex were detected 
in two purifications. 
 
 
 
 
Figure 17: Silver stain analysis of TAP method of Rad18-HA-TAP fusions 
Protein depletion throughout the purification and specific bands for the final eluates of the fusions 
indicate successful TAP for Rad18 fusions. The first three panels show the different steps of the 
purification for CTAP, NTAP and TAP alone. The volume loaded to the total volume of each 
fraction is shown in the parentheses. The fourth panel shows the final eluates of the fusions and the 
TAPalone of the same purification experiment loaded in a separate gel for better staining. The 
detection of distinct bands in the CB E of the NTAP fusion (first panel) was not improved when it 
was loaded 10 fold more in the next lane and also not reproducible in the separate gel for loading 
10-fold more of the final eluates alone (fourth panel). The reason for this discrepancy is unclear. 
Abbreviations: IgB Supt. – Ig beads Supernatant; IgB vor TEV – Ig beads before TEV; IgB after 
TEV – Ig beads after TEV protease cleavage ; TEV E – TEV protease eluate; CB F.T. – Calmodulin 
binding flow through; CB E – calmodulin binding eluate; CB B – calmodulin binding beads 
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3.2.7. LC-MALDI analysis of Rad18 TAP samples 
The final eluates of the TAP were processed as done before for the AID-TAP fusions. 
The peptides generated by trypsin digest were split into two fractions and each fraction was 
separately processed further. The peptides in the sample were subjected to reverse phase 
nano-LC. The nano-LC profile revealed specific peptide peaks for the Rad18 fusions against 
very low background peaks for the TAPalone (Figure 18). The separated peptides were 
spotted with the matrix on a MALDI target, which was analysed by the 4700 proteomic 
analyser. There were many peptides identified for the Rad18 fusions compared to the TAP 
alone control during MALDI analysis. For instance, in a particular experiment, there were 
1408 unique peptides identified in the NTAP-HA-Rad18 fusion sample while in the 
TAPalone, 1156 peptides were identified. The MALDI data were then analysed by the 
MASCOT software to identify potential interaction partners of Rad18. 
3.2.8. MASCOT analysis for Rad18 fusions 
The MASCOT analysis revealed more significant proteins for the Rad18 fusion samples 
than for the TAPalone control. For instance, in a particular purification, a list of 44 significant 
proteins was generated for the fusion sample, while the TAPalone samples produced a list of 
only 18 significant proteins. The 44 unique proteins included the bait protein, Rad18 and 
known interaction partners, Rad6 and ubiquitin. Table 3 shows a sample list of significant 
proteins identified for Rad18 fusion in one of the purifications. Although Rad6 was shown to  
Figure 18: The chromatogram of the nano-LC separation of peptides of Rad18-HA-TAP fusions 
and TAPalone. Specific peaks were detected for the fusions compared to the TAPalone. Key: Blue 
line – Rad18-HA-CTAP; Black line – NTAP-HA-Rad18; Pink line – TAPalone. 
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copurify with Rad18 in the western blot analysis of the TAP method, it was identified in the 
MASCOT analysis only with a single peptide and only in the CTAP fusion sample of a single 
TAP purification. It was identified in other samples sometimes with a non-significant score. 
New potential interaction partners of Rad18 were also identified with significant scores. 
The proteins that were considered for further analysis were those that met more than one 
of the following criteria of significance. Those that were identified: 1) in more than one 
sample or purification with a significant score and 2) with a reliable y (when the 
fragmentation occurs at the C-terminus of the peptide bond) and b (when the fragmentation 
occurs at the N-terminus) MS/MS fragmentation for a given peptide. A detailed description 
about the MS and MS/MS optics is given in the part 5.2.12 of the methods section. Table 4 
shows a shortened list of potential interaction partners of Rad18 with its known functions, 
based on these criteria. The original lists of the Rad18 fusions and TAP alone are provided in 
the Appendix 2. 
Several ribosomal proteins were identified as potential Rad18 interaction partners that 
are multifunctional proteins which have many different functions in the cell besides their role 
Table 3: An example of the primary list of the potential interactions identified for NTAP-HA-
Rad18 fusions 
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in ribosomes. The ribosomal protein (RP) L10 is known to be a structural and functional 
homolog of human QM and chicken Jun binding protein or Jun interaction factor (JIF)-1 
(Monteclaro and Vogt 1993; Chavez-Rios et al. 2003). The Jun binding protein was often 
identified with many significant peptides in the MALDI analysis of Rad18 fusions. This 
protein is considered as a tumor suppressor gene expressed in non-tumorigenic revertants of 
Wilm‟s tumor cells (Dowdy et al. 1991; Monteclaro and Vogt 1993). Several studies have 
revealed that the JIF-1 protein binds to c-Jun, inhibiting the activating protein 1 (AP1) 
function (Monteclaro and Vogt 1993; Chavez-Rios et al. 2003), thereby regulating the 
JNK/AP1 pathway. 
The RP S3a is yet another ribosomal protein known to play a role in cellular 
transformation and apoptosis (Naora and Naora 1999). The monoallelic disruption of the rat 
RPS3a which is identical to the v-Fos transformation effector protein 1 (fte1) gene in v-fos-
transformed fibroblasts resulted in the loss of the transformed phenotype (Kho et al. 1996). As 
an EBNA5 binding protein, fte1/RPS3a is involved in inhibiting growth and differentiation 
and plays a role in v-fos mediated cellular transformation (Lecomte et al. 1997; Kashuba et al. 
2005). Therefore this protein could also be linked to the regulation of JNK/AP1 pathway. 
Table 4: An overview of the known and interesting potential interaction partners identified for 
the Rad18-HA-TAP fusions. The number of significant peptides and the known function(s) are 
indicated for each protein. These short listed proteins were considered for further analysis. 
Abbreviations: C – CTAP fusion sample; N – NTAP fusion sample; T – TAPalone sample; the 
numbers (8) and (10) indicate the experiment numbers of two different purifications. 
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RPS3a also inhibits apoptosis in association with Bcl-2 by inhibiting PARP activity (Song et 
al. 2002). 
RP L18a contains two hydrophobic zipper-like domains that could bind to the Leucine 
Zipper motif of c-Jun and hence RP L18a is considered as a putative cellular regulator of the 
Jun protein (Gramatikoff et al. 1995). However this function has not been further 
characterised. 
The Rho GTPase activating protein 25 (RhoGAP25) could be implicated in the 
regulation of the JNK/AP1 pathway since Rho GTPases are essential for the activation of the 
JNK pathway upon DNA damage and Rho GAPs inactivate the GTPases by accelerating the 
intrinsic GTPase activity leading to the GDP-bound form. Rho GAP25 is also known to be 
downregulated in Burkitt lymphoma cells (Hummel et al. 2006). 
The Retinoblastoma binding protein 4 (RBBP4) homolog Chromatin Assembly Factor1 
(CAF-1) subunit has been linked to the Rad6 pathway by epistasis analysis in yeast (Game 
and Kaufman 1999). RBBP4 is also a part of histone deacetylase complex 1 (Nicolas et al. 
2000), histone deacetylase complex 3 (Nicolas et al. 2001), and histone deacetylase 
transferase 1 (Wolffe et al. 2000). Therefore RBBP4 seems to play a role in chromatin 
assembly, remodelling and modification. Besides, it could also be linked to the regulation of 
the PI3K/AKT pathway since overexpression of RBBP4 conferred radiation sensitivity on 
several cancer cell lines via dephospohorylation of Akt (Torres-Roca et al. 2005). 
All these protein interactions were found to be interesting for further analysis and 
experiments for confirmation by co-immunoprecipitation with Rad18 and characterisation of 
the functionality were then pursued. 
3.2.9. Immunoprecipitation attempts for confirmation of some potential 
Rad18 interaction partners 
The co-immunoprecipitation (Co-IP) experiments to confirm interesting potential 
interactions were attempted for RP L10/ JIF-1 with the exogenously expressed Rad18-HA-
CTAP fusion clones, since there was no antibody available for the endogenous chicken Rad18 
protein and the antibody that was available for the JIF-1 protein only detected the chicken 
protein. To avoid interference of the protein A moiety of the TAP tag during the IP, the cell 
extracts were subjected to TEV cleavage as done for the TAP purification and the TEV eluate 
was used as the input for the IP with JIF-1 antibody. An isotype matched antibody and lysate 
without antibody were used as controls. The precipitate was then analysed for co-precipitation 
of Rad18 using anti-HA antibody (Figure 19A). Rad18 was detected in the immune 
precipitate with the JIF1 antibody as well as the two controls and the background was not lost  
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Figure 19: Co-immunoprecipitation experiments for interesting potential Rad18 interaction 
partners. 
A) IP of Jun binding protein or JIF1 in DT40 cells expressing Rad18-HA_TAP fusions. The TAP 
extracts of Rad18 fusions were subjected to IgG binding and TEV cleavage to get rid of the 
protein A moiety of the TAP tag that may interfere with the IP. TEV E was used as the IP-input in 
this case. Immunoprecipitates of JIF-, isotype control and null antibody control were washed 
either with low-salt or high-salt buffer. Co-immunoprecipitation of Rad18 was analysed with anti-
HA antibody. 
B) & C) Immunoprecipitation of endogenous Rad18 in the human B cell line Raji, to analyse co-
precipitation of (B) RPS3a and (C) RBBP4. The total cell lysate input was incubated with Rad18 
antibodies along with appropriate controls as indicated. The Rad18 antibodies 339A and 340A 
are two antibodies obtained from Bethyl Laboratories, Inc that were raised against different 
epitopes of the human Rad18 protein. Rad6 was shown to co-precipitate with the Rad18 for the 
340A anti-Rad18 antibody. The immunoprecipitates were washed with either low salt or high salt 
buffers. 
D) Immunoprecipitation of endogenous RBBP4 in Raji cells.  
Abbreviations: IP – Immunoprecipitaion; TEV – Tobacco etch virus; JIF-1 – Jun interaction 
factor 1; RBBP4 – Retinoblastoma binding protein 4; RPS3a – Ribosomal protein S3a; TEV E – 
TEV protease eluate; IP - immunoprecipitate 
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even with high salt washes. The success of the IP for RPL10/JIF1 could also not be 
ascertained owing to the background bands from the proteinG beads at the height of 
RPL10/JIF1. Due to these technical problems, the Rad18-RPL10 interaction could not be 
confirmed by CoIP. 
In the meantime, a new Rad18 antibody with an IP potential became available for the 
endogenous human Rad18 protein. This reagent was used for CoIP experiments to confirm 
RPS3a and RBBP4, since antibodies for the human homologs of these proteins were also 
available. Figure 19B and 19C shows the IP immunoblots for the endogenous Rad18 protein 
in a human cell line, Raji. The success of the IP was confirmed by probing for Rad6, the 
known interaction partner of Rad18. The potential interaction of RPS3a with Rad18 was not 
evident in the IP though (Figure 19B). To confirm the interaction between RBBP4 and Rad18, 
CoIP was performed once with Rad18 as the bait protein and once with RBBP4 as the bait. 
The RBBP4 protein was not detectable in the IP with Rad18 antibody due to interference with 
the heavy chain signal as observed in the antibody without lysate control (Figure 19C). When 
the IP was performed with the RBBP4 antibody, Rad18 protein was not detectable in the 
precipitate (Figure 19D). Hence it was not possible to confirm the interaction between Rad18 
and RBBP4. 
3.2.10. Functional Link of Rad18 to the JNK pathway 
The c-Jun N-terminal kinases/stress-activated protein kinases (JNK/SAPK) regulate the 
phosphorylation of the AP1-like transcription factors, Jun/Fos and Jun/ATF heterodimers that 
are activated upon genotoxic stress. The JNK/SAPK are members of the MAP Kinase family 
that regulate cell survival by promoting DNA repair and apoptosis. The dual phosphorylation 
of SAPK/JNK is known to be activated upon DNA damage induced stalling of replication 
forks (Fritz and Kaina 2006). Since Rad18 is a key player in the recognition, response and 
repair of stalled replication forks, it could be hypothesised that Rad18 may have a role in the 
activation of the JNK/AP1 pathway. 
Some of the interesting potential interactions partners identified by the proteomic 
analysis of Rad18 indicated a potential role of Rad18 in the modulation of the JNK pathway, 
although the interactions could not be confirmed owing to technical bottlenecks of the DT40 
system. Independently, since Rad18 knockout DT40 cell lines were available to test the 
functional link of Rad18 to the JNK pathway upon DNA damage induced stalling of 
replication, Rad18 deficient and proficient DT40 cells were used to investigate this functional 
link. 
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Figure 20: MMS induced activation of the JNK pathway upon stalled replication in Rad18 
proficient and deficient DT40 cells 
A) The activation of the JNK pathway upon DNA damage in ψ- wild type vs. ψ- Rad18-/- and wild 
type Cre1 vs Rad18
-/-Δ
 DT40 cells. The cells treated with 1mM MMS for different time points were 
analysed for the activation of JNK pathway by immunoblotting for pJNK. 
B) Activation of the JNK pathway upon DNA damage induced stalled replication in ψ- wild type 
and ψ- Rad18-/- compared to that of ψ- Rad18-/-Δ single cell clones derived from the ψ- Rad18-/- 
cells. PonceauS stain is shown as a control for equal loading. 
C) Source: Bachl et al. 2006. The difference between the ψ- Rad18-/- and Rad18-/-Δ cells in the 
Rad18 knockout strategy. The knockout strategy used to generate the Rad18 knockouts (left) and 
qRT-PCR to analyse the mRNA transcripts of the two Rad18 knockout DT40 cells compared to 
wildtype (right). The exons 1 to 7 of the Rad18 gene are represented as boxes. The exons 3, 4 and 
part of exon 5 were replaced by loxP flanked resistance marker cassettes. These exons correspond 
to 46-209 amino acid residues of the Rad18 protein that code for essential and conserved parts of 
the RING domain, thereby abolishing the Rad6/Rad18 interaction and hence the PCNA 
ubiquitination function of Rad18. The qRT-PCR for the complete Rad18 coding region indicates 
loss of the targeted exons in the knockouts but an in-frame spliced mRNA transcript of smaller size 
in the Rad18
-/-Δ
 DT40 cells. 
Abbreviations: pJNK – phosphorylated JNK1 (54kDa) and JNK2 (46kDa); MMS – methyl 
methane sulphonate 
Results 
 
48 
The ψ- Rad18-/- DT40 cells were generated from the ψ- DT40 cells that have their 
pseudo-V genes deleted (ψ-) (Arakawa et al. 2004; Bachl et al. 2006). The two alleles of the 
Rad18 were inactivated using LoxP flanked blasticidin and puromycin resistance cassettes 
that replaced most of the RING domain (Bachl et al. 2006) (Figure 20C). 
These cells were treated with 1mM Methyl Methanesulfonate (MMS), a DNA alkylating 
agent, harvested at different time points and analysed by western blot for phospho-JNK1 
(46kDa) and phospho-JNK2 (54kDa) (abbreviated together as “pJNK”). The Rad18-/- cells 
showed clearly a lack of activation of the pathway when compared to the wild type cells 
(Figure20A), suggesting that Rad18 is involved in the activation of the JNK pathway upon 
DNA damage. 
In order to further analyse this novel function of Rad18, a Rad18
-/-Δ
 clone was also tested 
along with the parental wild type Cre1 DT40 cells for this knockout. These Rad18
-/-Δ
 cells had 
been generated by tamoxifen induced removal of the resistance cassettes which resulted in the 
generation of an in-frame spliced mRNA transcript lacking the RING domain (Bachl et al. 
2006) (Figure 20C). Surprisingly, these cells showed an increased activation of the JNK 
pathway (Figure 20A). From the known functional domains of Rad18 (Notenboom et al. 
2007), it could be speculated that despite the lack of the RING domain in the Rad18
-/-Δ
 
protein, the DNA binding domain was still retained. The in-frame spliced mRNA transcript in 
the Rad18
-/-Δ
 cells could potentially result in a truncated form of the protein that is able to 
bind to stalled replication forks but lacks the ability to perform its usual ubiquitination 
function. This could lead to a block or further delay in the repair of the fork resulting in an 
increased activation of the JNK pathway from these stalled forks. 
In order to test this assumption, in a joint experiment with Samantha Pill, a diploma 
student in our group, ψ- Rad18-/-Δ cell clones generated by tamoxifen induced removal of the 
resistance cassettes in the ψ- Rad18-/- cells were used. The ψ- wildtype, ψ- Rad18-/- parental 
and two ψ- Rad18-/-Δ single cell clones were treated with 1mM MMS and assayed for the 
activation of JNK pathway as before. The ψ- Rad18-/-Δ cell clones indeed showed an increased 
activation of the JNK pathway while the ψ- Rad18-/- parental cell line showed a complete lack 
of JNK activation compared to the ψ- wild type cells (Figure 20B). 
It thus appeared that a Rad18 protein lacking the RING domain was able to activate the 
JNK pathway, implying that the RING domain of Rad18 and hence the ubiquitination of 
PCNA was not required for this activation. This was confirmed by analysing the activation of 
DNA damage induced JNK pathway in ψ- parental DT40 cells and a ψ- PCNA K164R mutant 
that cannot be ubiquitinated (Figure 21A). The activation of JNK was observed to be almost 
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equal in both the cells indicating that PCNA ubiquitination status does not affect this 
activation. The ubiquitination status of PCNA was also verified by western blot analysis 
(Figure 21A). These results show that DNA damage induced activation of the JNK pathway 
by Rad18 is a novel function of Rad18, independent of its PCNA ubiquitination function. 
Since one of the potential Rad18 interaction partners identified, RBBP4 was linked to 
the regulation of the PI3K/Akt pathway via dephosphorylation of Akt, the potential role of 
Rad18 in this function was also tested. In order to verify this, the western blot analysis of 
MMS treated ψ- wild type vs. ψ- Rad18-/- and ψ- parental vs. PCNA K164R mutant was also 
probed for phosphorylated Akt (pAkt) (Figure 21B). It was observed that the presence or 
absence of Rad18 did not affect the activation of the Akt pathway and hence did not influence 
the role of RBBP4 in the dephosphorylation of Akt. This indicated that the phenotype 
observed for the activation of the JNK pathway was indeed biologically significant rather than 
being an incidental cell type specific difference. These results proved that Rad18 was required 
for DNA damage induced JNK activation that is not dependent on the RING domain and 
hence the ubiquitination function of the protein. 
Figure 21: 
A) The activation of the JNK pathway upon DNA damage in the ψ- parental and ψ- PCNA 
K164R mutant DT40 cells. The monoubiquitination status of PCNA in the wild type and mutant 
cells is also shown as a control for the assay. 
B) DNA damage induced activation of PI3K/Akt pathway in ψ- wild type vs. ψ- Rad18-/- and the 
ψ- parental and ψ- PCNA K164R mutant DT40 cells. 
PonceauS stain is shown as a control for equal loading. 
Abbreviations: pAkt – phosphorylated Akt protein; PCNA – proliferating cell nuclear antigen; 
PCNA-Ubi – monoubiquitinated PCNA 
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4. Discussion 
The study of protein interaction networks is vital to acquire a comprehensive 
understanding of cellular processes. Most of these processes are executed by multiprotein 
complexes. The identification and characterisation of the components of these complexes 
would provide a better understanding of the organisation of the proteome into functional 
entities. Rad18, the protein studied in this project, is a key mediator of the Rad6 pathway. It 
plays a role in SHM (Bachl et al. 2006) and is also involved in mediating DNA damage 
responses via the ubiquitination of the 9-1-1 checkpoint clamp (Fu et al. 2008). The 
recognition of forked and single-stranded DNA structures by Rad18 triggers its recruitment to 
the stalled replication forks (Tsuji et al. 2008) via direct interaction with RPA (Davies et al. 
2008). Consequently, it is becoming increasingly clear that Rad18 is a central player in many 
different pathways linked to DNA damage recognition, response and repair especially at the 
stalled replication fork. The study of the Rad18 interaction network was undertaken to 
understand more vividly the molecular interplay of different pathways modulated by Rad18. 
This requires the isolation of native protein complexes to near homogeneity. Affinity 
chromatography is one of the most popular approaches to isolate protein complexes. In 1999, 
B. Seraphin and his research group developed a method for the purification of native protein 
complexes from yeast, the TAP method which is based on a combination of a high affinity 
purification step with a subsequent lower affinity purification step (Rigaut et al. 1999). The 
first step removes most of the nonspecific proteins in the extract, and allows a crude isolation 
of the fusion protein with its associated interaction partners. The removal of any remaining 
contaminating proteins from this first eluate requires a second purification step. It was found 
that even very small quantities of native complexes could be isolated with high yield using 
this method in the yeast system (Rigaut et al. 1999). 
The introduction of the TAP method substantially improved the purification and 
systematic genome-wide characterisation of protein complexes in yeast (Rigaut et al. 1999; 
Puig et al. 2001; Gavin et al. 2002). This approach was adapted to higher eukaryotic cells 
often with modifications to implement a more effective method that was comparable to the 
yeast system. The iTAP strategy, for instance, comprises the conventional TAP approach 
combined with suppression of the corresponding endogenous protein by RNA interference in 
Drosophila melanogaster Schneider cells (Forler et al. 2003) or in mammalian cells 
(Bertwistle et al. 2004). In human cells, the TAP method has been applied for instance in 
HEK293, an embryonic kidney cancer cell line (Bouwmeester et al. 2004), and in the Raji, 
human B cell line (Tobollik 2007). 
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However, the TAP method has not been used in a vertebrate system that could offer the 
specific advantages of the yeast system. The DT40 chicken B cell line presents the possibility 
to knockout the endogenous protein owing to its high genetic stability and easy manipulation 
of the genome. The knockout of the endogenous gene followed by the expression of the TAP 
tagged fusion protein allows the assessment of the functionality of the fusion and avoids 
competition for interaction partners with the endogenous protein. Moreover the DT40 B cell 
line also constitutes a well established system for the study of gene conversion and SHM. 
Consequently, we decided to combine the advantages of the TAP method with DT40 to 
establish a system which parallels many advantages of the TAP combination with yeast. 
The TAP method followed by mass spectrometric analysis is a valuable approach that 
provides an outline of the network of protein complexes thereby presenting a more 
fundamental perspective on the molecular communication of biological processes. This 
approach was established using AID-TAP constructs and applied to study the Rad18 
interaction network in the DT40 chicken B-cell line. For this the GOI was tagged to the TAP 
tag. There are two alternatives to express the TAP tagged fusion protein, namely from the 
endogenous loci that could be modified to express the TAP tagged fusion protein or from 
exogenous expression vectors stably transfected into the cells. Ideally, endogenous expression 
of the TAP fusion is expected to achieve expression levels similar to the endogenous protein. 
However, modifying the endogenous loci may also result in the disruption of the promoter 
and regulatory elements in the 5‟-region of the gene that controls its expression in case of the 
N-terminal modification. This may even lead to loss of expression of the gene. Alternatively, 
since exogenous expression vectors carrying AID-CTAP and NTAP-AID fusions were 
already available to test the approach, the latter alternative was opted for this study. The 
pCAG and pZome expression vectors that were tested differ by the type of promoter driving 
the expression of the fusions. 
The AID-TAP fusions were expressed in the AID
-/-
 DT40 cell line. The expression 
attainable by these vectors was measured at the mRNA and protein levels by qRT-PCR and 
western blotting, respectively. The protein amounts bear the final influence on the success of 
the purification, and owing to differences in the transcriptional and translational regulation, 
mRNA amounts need not necessarily correlate with the protein levels. However, the protein A 
moiety of the TAP tag can bind any antibody probed in the western blot analysis and generate 
very strong signals. Due to this reason, the signal of the fusion protein probed with the AID 
antibody for AID fusions or the HA antibody for the Rad18 fusion protein cannot be 
compared to the signal of the endogenous protein. Hence the comparison of the exogenous 
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fusion expression to the endogenous expression of the GOI was made only in the context of 
the mRNA amounts. 
The qRT-PCR results indicated that the pCAG served as an overexpression system that 
could be used if needed, while the pZome vector provided expression at or close to 
physiological levels. Previous TAP purifications in vertebrate systems have often involved 
mild to moderate overexpression of the fusion protein (Bertwistle et al. 2004; Bouwmeester et 
al. 2004). The purifications performed with AID-TAP fusions in the human Raji cell line in an 
earlier study was successful with 6-fold overexpression of the AID-CTAP fusion and 30-fold 
overexpression of the NTAP-AID fusion compared to the endogenous AID in the context of 
mRNA levels (Tobollik 2007). The AID-TAP fusion protein expression in the DT40 cell line 
was compared to the protein amount that was used to perform a successful TAP in the Raji 
human cell line. From this comparison, it was deduced that a protein amount corresponding to 
5-10 mRNA copies per hprt copy in the DT40 cell line was sufficient to make a successful 
TAP purification in the chicken B cells. 
The Rad18-HA-CTAP and NTAP-HA-Rad18 fusions were expressed from the pZome 
expression vector in rad18
-/-
 DT40 cells, since we could obtain clones expressing close to 
physiological to mild overexpression of the fusion protein using this vector. Comparing the 
relative band intensities of the fusions detected in the western blot to the relative mRNA 
copies determined by qRT-PCR, it was observed that there was a correlation between the 
mRNA and protein expression levels for both the AID-TAP clones as well as the Rad18-HA-
TAP clones. Moreover the differences in the exogenous expression levels of the fusion 
protein in the various clones offered the possibility to choose the clone with an appropriate 
expression level required for optimal proteomic analysis. A clone with a mild overexpression 
at nearly 10 fold mRNA copies was used in this study. A higher overexpression of the fusion 
protein from the pCAG vector may also be employed in the future to achieve higher signal to 
noise ratio in the MALDI analysis. However, one has to be cautious in interpreting the 
interactions identified from an overexpression system, since this may attract non-specific 
interactions. This necessitates the confirmation of the interactions identified by an 
independent assay (Bertwistle et al. 2004). 
The ability of the fusion protein to form complexes is crucial for studying the protein 
interaction networks. Therefore, the Rad18 fusion complexes were analysed by native PAGE 
and it was observed that the fusions do form complexes of more than 720kDa in size. The 
lack of an antibody for chicken Rad18 protein at this time limited the comparison of this 
complex to the endogenous context in the wild type and rad18
-/-
 cells. When an antibody that 
cross reacts with the chicken Rad18 protein would be found, it could be used to characterise 
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the Rad18 complexes in a physiological context in future. A native PAGE is a rough 
estimation of the complexes and gel filtration or sucrose gradient ultracentrifugation methods 
might provide an even better alternative to estimate the exact complex size. The native PAGE 
technique may instead be used to monitor complex integrity during TAP purification or to 
assess complex changes upon induction of DNA damage in the cells. 
Cellular localisation has a direct bearing on the functionality of the protein and its 
interaction partners. Therefore, it was interesting to study the localisation of the Rad18 
fusions. The localisation of the endogenous Rad18 protein is known to be affected by the 
ubiquitination status of the protein (Miyase et al. 2005). The non-ubiquitinated Rad18 is 
predominantly detected in the nucleus while the monoubiquitinated
 
form is specifically 
localized in the
 
cytoplasm. In fact, it has been speculated that monoubiquitination serves to 
export the protein from the nucleus to the cytoplasm. The polyubiquitinated forms of Rad18 
have been shown to trigger the degradation of the protein by the proteosome in vitro (Miyase 
et al. 2005). In this study, the Rad18-HA-TAP fusion proteins were found in both the nuclear 
and cytoplasmic fractions. It is interesting to note that a specific band of lower molecular 
weight was also detected but only in the nuclear fraction, which may correspond to the non-
ubiquitinated species of the fusion in the nucleus. 
The nuclear fraction of the TAPalone negative control also showed the presence of the 
TAP tag protein. This might indicate passive diffusion of the protein owing to its small size of 
20kDa or may be due to slight contamination of the cytoplasmic fraction during the 
separation. The PAP reagent used to detect the TAP tag and the fusions is known to generate 
a strong signal and hence even mild contamination could be detected with a strong signal. The 
cellular localisation pattern of some of the known interaction partners of Rad18, namely Rad6 
(Koken et al. 1996; Lyakhovich and Shekhar 2003), UBC13 (Ulrich and Jentsch 2000; Hoege 
et al. 2002) and PCNA (Szuts et al. 2005) was also found to be consistent with earlier 
findings. 
Finally, an important aspect to be considered before performing a TAP was to ascertain 
that the fusion protein was able to reconstitute the function of the knocked-out endogenous 
protein. The TAP tag being large (≈ 20kDa) could influence the folding of the protein and/or 
the availability of the active site(s) of the protein to perform certain functions. The 
functionality of the fusion protein is assessed in terms of the known functions of the protein. 
The type of fusion, whether C-terminal or N-terminal could also influence the functionality of 
the protein, as seen for AID-TAP constructs earlier (Tobollik 2007). The AID-CTAP fusion 
was functional and the NTAP-AID fusion was non-functional for SHM, as assessed by the 
rate of SHM using a GFP reporter assay in human and DT40 cells (Tobollik 2007). 
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The Rad18 functionality was analysed by assaying the cell survival upon DNA damage 
(Tateishi et al. 2000; Yamashita et al. 2002). Analysis of the reconstitution of the PCNA 
ubiquitination function (Hoege et al. 2002) or of the influence on the rate of SHM (Bachl et 
al. 2006) were the other alternatives to assess the functionality of Rad18 fusions. However it 
is known that a certain degree of background PCNA ubiquitination does occur in Rad18 
knockout cells (Szuts et al. 2006; Zhang et al. 2008). Also, SHM is a process achieved by 
complementary paths (Rada et al. 2004), some of which do not involve Rad18 and although 
the knockout of Rad18 showed a reduced frequency of SHM, it is not entirely abolished 
(Bachl et al. 2006). Therefore determining the sensitivity of the fusions to cisplatin compared 
to the wild type and rad18
-/-
 cells was selected as the best alternative to assess the 
functionality of the Rad18 fusions. 
The methylcellulose colony survival assay showed that both the Rad18-HA-CTAP and 
NTAP-HA-Rad18 fusions were able to reconstitute the sensitivity of the rad18
-/-
 cells to 
cisplatin induced DNA damage. In fact the slight overexpression of the NTAP fusion 
appeared to render the cell survival even higher than that of the wild type, while the survival 
of the CTAP fusion resembled that of the wild type cells. This small difference might be due 
to the influence of the TAP tag on protein folding and the distance of the tag to the positions 
of the known functional domains of Rad18 (Notenboom et al. 2007). Despite this small 
difference, both the fusions were evaluated to be functional and the TAP tag did not seem to 
interfere with all interactions of the protein. 
The TAP fused proteins thus characterised for expression, cellular localisation, complex 
formation and functionality were then subjected to TAP. The TAP technique was optimised 
earlier in the human Raji cell line by Stephanie Tobollik in the lab such that the protocol 
could be used for different cell types (Tobollik 2007). The technique was carried out in the 
DT40 cells as performed by S. Tobollik in the Raji cell line, except that the number of DT40 
cells used for protein extraction was doubled since the DT40 cells are much smaller than the 
Raji cells. The short doubling time of DT40 cells was convenient for making this increase 
practically feasible. 
The Western blot analysis showed that the AID-TAP fusions were successfully 
recovered in the purification process and RPA – a known interaction partner of AID 
(Chaudhuri et al. 2004) – was also co-purified. The binding of the Protein A moiety to the IgG 
beads was successful with a variation of 50% to 90% binding in independent experiments and 
different fusions within an experiment. There was a 60% to 90% variation in the efficiency of 
the TEV cleavage step but the elution of the cleaved protein was nearly 95 to 100%. The 
calmodulin binding and elution was the least efficient step, since much of the protein was lost 
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in the flow through or remained bound to the beads during elution and the final recovery was 
only 3 to 5% of the input. In the western blot analysis of the TAP fractions, degradation 
products of the fusions were sometimes observed. It is not known whether this might be due 
to the conditions of the purification itself, especially at the TEV protease cleavage step, or due 
to an overnight Ig binding step. Despite this mild degradation, it was possible to recover the 
full length protein in the final elution step of the TAP purification. 
Similarly, Rad18 fusions were also successfully purified and Rad6, a known interaction 
partner of Rad18, was copurified. The recovery throughout the purification was much more 
efficient for the Rad18 fusions than for the AID fusions. The Ig binding varied within the 
range of 70 to 90% and the TEV cleavage step was always around 90% efficient. The final 
calmodulin binding and elution recovery was also substantially better for Rad18 fusions than 
for the AID fusions. The calmodulin binding was nearly 40 to 50% while about 30% or more 
of the TEV eluate was lost in the calmodulin flow through. The final eluate recovered was 
nearly 10 to 25% for the CTAP fusion and only 3-5% for the NTAP fusion. 
It is possible that the long overnight Ig binding step might have an impact on complex 
integrity. But the co-purification of the known interaction partners, RPA with the AID fusion 
and Rad6 with the Rad18 fusion, showed that the complexes are at least partly intact. This 
could be verified by performing native PAGE of the different fractions of the purification. 
There are several possibilities to optimise the TAP technique in DT40 cells. The calmodulin 
elution might be improved for better recovery of the fusion protein by investigating the 
recovery with increasing salt or EGTA concentrations in the elution buffer. There are also 
possibilities to use other types of TAP tags which might be even more efficient in recovering 
the bait protein. For instance, a modified TAP tag in which the Protein A moiety was replaced 
by STREP tag to avoid the TEV cleavage step (Gloeckner et al. 2007) might be an alternative 
to test. 
The recovered final eluate of the TAP purification was concentrated by TCA 
precipitation before further processing. Complex mixtures of proteins are usually processed 
by in-solution trypsin digest, which is more efficient in digestion of the proteins and recovery 
of peptides than the in-gel trypsin digestion. However, due to technical problems with 
chloroform-methonol precipitation, this method could not be implemented for the final TAP 
eluates. Instead, the final eluate containing a mixture of different proteins was run on SDS-
PAGE gel for about 1cm and cut out to perform an in-gel tryptic digest. Although it is 
possible to analyse the final eluate by a longer SDS-PAGE, followed by visualisation of 
proteins using coomassie or deep purple
®
 staining methods in order to cut out individual 
bands for in-gel trypsin digest, this approach was not implemented. This is because this 
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approach largely depends on the sensitivity of the staining methods used and the amount of 
protein recovered by the TAP method, both of which were variable between different 
experiments. 
Despite the less efficient in-gel trypsin digest, the nano-LC detector showed specific 
peptide peaks for the fusion proteins compared to a lower background in the TAPalone 
control. The peaks for the Rad18 samples were even more distinct than for the AID samples. 
In many of these nano-LC profiles, however, high peaks appeared after the gradient 
separation which may indicate the presence of unresolved peptides or inefficiently digested 
proteins. The resolution of the peptide peaks for the samples during the gradient separation 
might be improved and the unresolved/undigested peaks may be avoided by adopting in-
solution tryptic digest. 
The separated peptides were subjected to MALDI TOF-TOF analysis in the 4700 
proteomic analyser from Applied Biosystems. The LASER induced ionisation of the peptides 
is followed by the flight of the peptide in an electric field across a vaccum chamber. The mass 
of the peptide is calibrated according to the TOF properties of the peptides ionised. The 
peptides thus identified from each retention spot on the MALDI target were selected in a 
subsequent MS-MS optics analysis in order to identify the peptide sequence with higher 
accuracy using the MASCOT analysis software. There were more peptide precursors for 
MS/MS analysis for the fusions than for the TAPalone. The analysis of the AID samples by 
MASCOT yielded potential interaction partners previously identified in human cells. The bait 
protein was also identified with a significant score for the AID fusions. There were also other 
proteins identified for AID but without an obvious relevance to AID function. Although RPA 
was shown to co-purify with the fusion by western blot analysis, it was not identified in the 
MALDI analysis. The reason for this may be that the ionisation of the peptides upon LASER 
stimulation was not optimal to detect the protein by the LC-MALDI approach. This reason 
could be validated by performing a different MS approach such as the Orbitrap which is an 
electrostatic ion trap with an electrospray ionization source (ESI) technique. Since the bait – 
AID and previously identified interactions were found with significant scores by the LC-
MALDI approach, it was concluded that the TAP method followed by LC-MALDI analysis 
was successfully adapted to the DT40 cell line to investigate the protein interaction networks 
of any protein of interest. 
An improved trypsin digest and recovery of peptides or overexpression may be opted to 
obtain a higher signal to noise ratio. Besides these sample processing improvements, the 
sensitivity of the MALDI is also a factor in obtaining optimal protein lists. A MALDI 
analyser with higher sensitivity or an entirely different MS approach such as the Electro spray 
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ionisation method may also be used to obtain a better or different list of proteins, since 
different and/or more peptides may be ionised. A recent study comparing nanoLC –MALDI 
MS/MS and nanoLC-ESI-MS/MS techniques, showed that coupling nanoLC with both ESI 
and MALDI ionisation interfaces improved coverage, reduced suppression of ionization and 
improved quantitation, particularly in complex samples (Yang et al. 2007). The first eluate of 
the TAP may also be analysed to obtain a better identification of the interacting proteins that 
may be less abundant in the complex. However, it must be distinguished that there may be a 
chance of some specific interaction partners of the bait being identified in the negative control 
if the first purification eluate was used, since RPA or Rad6 was lost only in the second 
purification step in the TAPalone control.  
It was also observed that the NCBI Gallus database generated better protein lists than 
Swissprot and entire NCBI databases. This was probably because the swissprot database is a 
curated database that is optimal for the AID TAP samples analysed in a human cell line 
(Tobollik 2007), but was not well updated for chicken protein sequences. On the other hand, 
the entire NCBI database was very huge containing more ambiguous sequences. In this case, 
the moderately conserved chicken proteins could likely not be identified by homology with 
other taxonomic groups. The NCBI database nevertheless did contain sequences of the 
chicken proteins that were constantly updated, so when the MASCOT analysis was performed 
with a manually downloaded database from NCBI for sequences restricted to those of Gallus 
gallus, the result of the analysis improved significantly. The only drawback of this approach 
was the fact that many chicken protein entries were initially made as hypothetical proteins and 
these would still interfere with the identification of the name of the protein. For instance, even 
the bait protein Rad18 was identified as “hypothetical protein” with very many peptides, and 
identified as Rad18 only upon blasting the sequence of the hypothetical protein. However, this 
is expected to be a temporary problem of the database and analysing the same experimental 
MALDI data again in the future could generate more and more refined protein lists. 
In summary, the approach is feasible and valuable in the DT40 system. The advantages 
of the combination of the DT40 system with the TAP method and proteomic analysis may be 
considered comparable to the yeast system in which the TAP method was originally 
established. This combination can be used as a tool to understand complex biological 
networks in vertebrates. Such an extensive elucidation of TNFα/NF-κB signalling has been 
achieved using the TAP method in human HEK 293-cells (Bouwmeester et al. 2004) and easy 
genetic manipulation might allow similar extensive studies on cellular processes in the DT40 
system. The current bottleneck of the approach in using DT40 cells is the limited availability 
of antibodies for chicken proteins. A curated chicken database comparable to the swissprot 
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database, devoid of ambiguities and hypothetical proteins might offer an additional advantage. 
But these bottlenecks are only temporary, and this approach may be applied for the analysis of 
other factors involved in somatic hypermutation and components of the Rad6 pathway, 
leading to an understanding of the cellular networks that may link these two processes in the 
B cell. 
The MALDI analysis of Rad18 yielded the bait protein with the most significant score. 
The known interaction partners Rad6 and Ubc13 were also identified although only once with 
a single peptide. The Rad18 fusion samples also yielded interesting new potential interactions 
with many interesting functions, some of them also being multifunctional proteins. The 
relative number of unique proteins identified for the fusions and the TAPalone indicated that 
as many as 47 and 36 new potential interaction partners were identified for the Rad18-HA-
CTAP fusion and NTAP-HA-Rad18 fusions respectively, after substracting the background 
proteins identified in the TAPalone. These substracted lists consisted of unique proteins many 
of which were multifunctional ribosomal proteins, RNA binding and splicing proteins and 
DNA binding proteins. There were also a few uncharacterised protein entries of unknown 
function. 
The proteins that met more than one of the following criteria of significance were 
considered for further analysis: 1) those that were identified in more than one sample or 
purification with a significant score and 2) with a reliable MS/MS fragmentation for a given 
peptide. The reason for this was because there was very low chance that a false positive 
interaction could be identified more than once in different purifications and different types of 
fusions. Further, the MS/MS fragmentation gives the reliability of the peptide(s) with which 
the protein was identified. Therefore, the better the identification of the fragmentation pattern, 
the higher the accuracy of the sequence of the peptide identified. However, one must keep in 
mind that common contaminants such as keratin, trypsin, actin and tubulin also meet these 
criteria and hence the results of the MALDI analysis only generates a list of potential 
interaction partners that would have to be confirmed by functional analysis. 
Some of the multifunctional proteins that were identified as potential Rad18 interaction 
partners were previously linked to the regulation of the JNK/AP1 pathway which is known to 
play a role in the cellular decision between apoptosis and survival during genotoxic and 
cytotoxic stress. These proteins, the Jun binding protein (alias JIF1 or RPL10), the ribosomal 
proteins S3a and L18a and RhoGAP25, were identified in independent TAP eluates and 
Rad18 C- and N- terminal TAP fusions. The ribosomal proteins are conventionally known for 
their function in translation (Roger A. Garrett 2000), but some of these proteins have been 
known to perform extraribosomal functions. 
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The ribosomal protein (RP) L10, a structural and functional homolog of human QM and 
chicken Jun binding protein or Jun interaction factor (JIF-1), is known to regulate the c-Jun 
protein although it does not resemble previously identified Jun regulators (Monteclaro and 
Vogt 1993; Chavez-Rios et al. 2003). The Jun binding protein is known to be a Wilm‟s tumor 
suppressor that may be involved in inhibiting Jun induced transformation (Dowdy et al. 1991; 
Monteclaro and Vogt 1993) and is also known as an inhibitor of the c-Jun protein in its 
activating protein 1 (AP1) function (Monteclaro and Vogt 1993; Chavez-Rios et al. 2003). 
The RPS3a or FTE1 has been implicated in cellular transformation and apoptosis (Naora 
and Naora 1999), since the disruption of this gene in v-fos-transformed fibroblasts resulted in 
the loss of the transformed phenotype (Kho et al. 1996). It is an EBNA5 binding protein 
which is involved in inhibiting growth and differentiation or apoptosis regulating functions 
(Lecomte et al. 1997; Kashuba et al. 2005). It as also known that Bcl-2 in association with 
RPS3a is able to inhibit Poly (ADP-ribose) polymerase activity and in the absence of RPS3a, 
Bcl-2 failed to inhibit PARP activity. These results suggest that RPS3a may be involved as an 
inhibitor of apoptosis (Song et al. 2002). It has been found that RPS3a is involved in drug 
sensitivity only when cytotoxicity includes DNA damage (Hu et al. 2000). 
The RPL18a is a putative Jun regulator (Gramatikoff et al. 1995) since it was shown to 
be able to bind to the leucine zipper motif of c-Jun. However there has been no further study 
published on this function. 
Another interesting potential interaction partner identified was the RhoGAP25, that has 
been found to be downregulated in Burkitt lymphoma cells (Hummel et al. 2006), but there 
are no other functional characterisation of this protein. RhoGTPase family genes are cancer 
associated genes since genetic alterations in these genes lead to carcinogenesis through the 
dysregulation of Rho/Rac/Cdc42 – like GTPases. The Rho-GTPases are also essential for the 
activation of the JNK pathway upon DNA damage (Fritz and Kaina 2006). Rho GTPase 
activating proteins (Rho GAPs) inactivate the GTPases by catalysing the intrinsic GTPase 
activity to its GDP-bound form. Therefore in may be speculated that Rho GAP25 may also be 
involved in the regulation of the JNK pathway in this manner. 
Besides these proteins, the RBBP4 was also identified as potential interactor of Rad18 
with significant scores. The RBBP4 seems to be implicated in chromatin assembly, 
remodelling and modification. It is a homolog of the yeast Chromatin Assembly Factor1 
(CAF-1) subunit C which has been linked to the Rad6 pathway by epistasis analysis (Game 
and Kaufman 1999). In Saccharomyces cerevisiae, CAC1, CAC2 and CAC3 are the three 
subunits of CAF-1, the deletion of any of which reduces the telomeric gene silencing and 
confers an increase in UV sensitivity. In this study, cac1 deletion in Rad18 and Rad6 mutants 
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did not increase the UV sensitivity of these cells, indicating an epistatic relation between the 
two genes. RBBP4 is also a part of the histone deacetylase complex 1 (Nicolas et al. 2000), 
complex 3 (Nicolas et al. 2001), and the histone deacetylase transferase 1 (Wolffe et al. 2000). 
Therefore the RBBP4 and Rad18 interaction could be involved in the influence of 
chromosome structure and modification. The overexpression of RBBP4 was concurrent with 
the dephosphorylation of Akt, suggesting that this function of RBBP4 may be mediated by 
antagonising the Ras pathway (Torres-Roca et al. 2005). The RBBP4 overexpression 
conferred radiation sensitivity on several cancer cell lines through the dephosphorylation of 
Akt protein. Therefore RBBP4 could also be linked to the regulation of PI3K/AKT pathway 
(Torres-Roca et al. 2005). 
Thus the most significant potential interaction partners of Rad18 indicated a potential 
role of Rad18 in the modulation of the JNK/AP1 pathway, PI3K/Akt pathway and PARP 
inhibition. Since antibodies for chicken proteins are limiting but the strength of DT40 genetics 
was foreseeable, the functional analysis of the link between Rad18 and the JNK/AP1 pathway 
and the PI3K pathway were carried out in parallel to the co-immunoprecipitation experiments 
to confirm the interactions. 
A number of immunoprecipitation (IP) approaches were carried out to confirm these 
interactions. Owing to lack of an antibody for chicken Rad18 protein, an IP of JIF-1 was 
attempted in the Rad18 fusion expressing clones after the extracts were subjected to TEV 
cleavage and elution. The Rad18 TEV-cleaved fusion was detectable in the precipitate, but 
also in the isotype and null antibody controls. Hence it was problematic to confirm the Rad18-
JIF1 interaction in DT40 cell line by an IP method. The success of the IP was also not 
ascertained since the protein G and light chain interfered with the detection of JIF1. 
Since an antibody with an IP potential for the human Rad18 protein has recently become 
available, a successful IP was established in the Raji human cell line with this reagent, which 
was verified by co-precipitation of Rad6. Antibodies for human RPS3a and RBBP4 were also 
available and where probed to verify their interaction with Rad18. It was observed that the 
RPS3a was not detectable in the precipitate and it was difficult to detect RBBP4 due to 
interference of signal from the heavy chain. The use of Trueblot
®
 secondary antibodies also 
did not overcome the problems of heavy and light chains. The IP with RBBP4 antibody also 
did not co-precipitate Rad18, but the success of this IP could not be controlled to derive 
conclusions. 
While a positive co-IP is a definite a proof of interaction, a negative co-IP does not 
necessarily imply that the interaction is not true. Further, the interaction may be specific for 
chicken and not for human. Lack of antibody for chicken proteins could hence be termed as a 
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“DT40 problem” and might be solved by tagging the proteins of interest to epitopes such as 
FLAG, MYC, etc. Such exogenous IP methods might be considered as a general solution to 
this problem. In order to perform such IPs for exogenous proteins, Rad18-HA fusions 
constructs in the pZome vector have already been generated (vide, methods). Other types of 
confirmation for the interactions may also be attempted, such as yeast two-hybrid assays, 
bimolecular fluorescence complementation, co-immune fluorescence, etc. For organisms that 
offer powerful genetic analysis methods such as the DT40 cell line, phenotypic analyses could 
also be used to confirm the functional significance of protein interactions. 
Since many proteins identified by the MALDI analysis of Rad18-TAP eluates were 
implicated in the regulation of the JNK/AP1 pathway, a potential functional link of Rad18 to 
this pathway was analysed. 
Exposure to genotoxic stress leads to cellular responses that affect cell survival via the 
stimulation of expression of various genes. This transcriptional activation is mediated by 
phosphorylation induced activation of pre-existing transcription factors such as c-Jun, c-Fos, 
ATF2, SRF-TCF, CREB and NFκB. The knockout of even one of these transcription factors 
impairs cell survival upon DNA damage. The SAPK and JNK regulates the phosphorylation 
of the AP1-like transcription factors and are both phosphorylated upon DNA damage induced 
stalling of replication forks (Fritz and Kaina 2006). 
Since the activation of the JNK/AP1 pathway by DNA damage induced stalling of 
replication forks is already known (Fritz and Kaina 2006), it was imperative to perform 
independent functional assays to test whether this process also involved Rad18. For this, ψ- 
wild type and ψ- Rad18-/- DT40 cells were treated with 1mM MMS and immunoblotted for 
phospho-JNK (pJNK). The JNK proteins are phosphorylated by Mitogen activated protein 
kinase kinases (MAP2Ks) that activates the JNK proteins triggering the downstream 
signalling cascade of the JNK pathway. Hence pJNK was assessed as the measure of the 
activation of the JNK pathway. The results indicated that there was barely any detectable 
activation of the JNK pathway in the ψ- Rad18-/- DT40 cells, while the wild type showed an 
activation of the pathway. However, when the Rad18 knockout in Cre1 DT40 cells, the 
Rad18
-/-Δ
 was tested, the activation of the pathway was substantially increased when 
compared to the wild type control. The differences between the two Rad18 knockouts is that 
the ψ- Rad18-/- cells have the knockout resistance cassettes in the Rad18 loci and the 
resistance cassettes have been removed in the Rad18
-/-Δ
 giving rise to an in-frame spliced 
mRNA lacking the RING domain (Bachl et al. 2006) but retaining the SAP domain 
responsible for the binding of Rad18 to the DNA (Notenboom et al. 2007). This implies that 
the Rad18 function of the RING domain and hence the ubiquitination function is not required 
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for the JNK activation. This was indeed found to be true when the ψ- PCNA K164R mutant 
and its parental ψ- cells were tested in a similar fashion. The results showed that the activation 
of the JNK pathway was similar in these cells, both being proficient for Rad18 and the PCNA 
mutant being incapable of ubiquitination. 
These results were further confirmed in a combined experiment with a diploma student 
by performing the assay in two independent single-cell ψ- Rad18-/-Δ clones generated de novo 
from the ψ- Rad18-/- cells. It could be seen that the results were consistent with the newly 
generated ψ- Rad18-/-Δ cells as well. Thus there is substantial evidence of a novel Rad18 
function in the activation of DNA damage induced JNK activation not involving the RING 
domain or PCNA ubiquitination. 
Since RBBP4 plays a role in the dephosphorylation of Akt, the effect of Rad18 on the 
DNA damage associated activation of the PI3K/Akt pathway was also investigated in Rad18 
proficient and deficient DT40 cell lines. It was found that DNA damage induced 
phosphorylation of Akt was not affected by the presence of absence of Rad18. However, this 
assay may serve as a biological verification that the effects measured by the JNK activation 
assay were indeed due to a biological impact of Rad18 on the JNK pathway and not due to 
clonal differences between the Rad18
-/-
 and Rad18
-/-Δ
 cell types. 
The activation of the JNK pathway upon DNA damage had been known for quite some 
time (Bode and Dong 2003; Dent et al. 2003) and the activation of the JNK pathway by DNA 
damage induced stalling of replication forks was thought to be mediated by DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs) and Cockayne syndrome protein CSB (Fritz and 
Kaina 2006). In the present study, a novel role of Rad18 in MMS induced activation of the 
JNK pathway was identified, although it is still not known whether this function is mediated 
by Rad18 directly or via potential interaction partner(s). 
One might think that the activation of JNK pathway during transcription coupled repair 
is mediated by CSB, during double strand break repair via DNA-PKcs and the activation of 
JNK pathway during repair of stalled replication could then be mediated via Rad18. However, 
this would not explain why the inactivation of either of these components would lead to a 
defect in JNK activation upon MMS treatment, which results in DNA lesions that mostly 
activate the BER and Rad6 pathways. This leads to a new question: Is DNA-PKcs and/or CSB 
epistatic with Rad18? It would therefore be interesting to answer this question by testing the 
effect of multiple knockouts of these three genes, individually and in combination, on the 
activation of the JNK pathway upon DNA damage. The DT40 Cre1 system offers the 
possibility to embark on such an approach. 
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Alternatively, the activation of JNK pathway upon DNA damage by Rad18 may be a 
specific feature of the DT40 cell type or may be specific for Gallus gallus species. In order to 
ascertain this, one may also investigate the role of Rad18 in the activation of JNK pathway 
upon DNA damage in other cell lines and/or other species. 
Future perspectives 
Reconstitution of Rad18 in the Rad18
-/-
 cells is expected to prove the novel function of 
Rad18 in the activation of JNK pathway from the stalled replication forks and experiments are 
already ongoing to meet this requirement. Since the Rad18 protein is already well 
characterised for its various functional domains (Notenboom et al. 2007), another future 
perspective would be to map the domain of the Rad18 protein that is involved in this novel 
function by mutational analysis. 
The activation of the JNK pathway might be mediated by increasing the kinase activity 
or reducing the phosphatase activity. Hence the ability of Rad18 to enhance upstream kinases 
and/or inhibit upstream phosphatases of the JNK pathway could be investigated to understand 
the mechanism of activation of the JNK pathway by Rad18. It would also be important to 
study the biological effect(s) of the JNK activation to know the impact of this novel function 
of Rad18 on cell survival and apoptosis, since the downstream targets of JNK/AP1 pathway 
affect both (Shaulian and Karin 2002). The role of Rad18 on other pathways such as the 
NFκB pathway, other MAPK signalling pathways, and cell cycle checkpoint signalling, Ig 
gene diversification, etc could also be investigated as the recent findings indicate the 
involvement of Rad18 in some of these signalling pathways or processes besides its classical 
role in the Rad6 pathway (Bachl et al. 2006; Bi et al. 2006; Szuts et al. 2006; Dávid Szüts 
2008; Davies et al. 2008; Fu et al. 2008). 
An improved TAP procedure in combination with a more sensitive MS analysis would 
also be pursued and the new potential interactions identified would be confirmed by 
optimising the IP protocol for endogenous human Rad18 protein and also by IP using the 
exogenous HA tagged Rad18 and Myc tagged potential interaction partners in DT40 cells. 
The Rad18 fusions may also be overexpressed and analysed by more sensitive mass 
spectrometric approaches to identify new potential interactions that may substantiate the novel 
link to the JNK pathway and also may provide interaction information linking Rad18 to other 
DNA damage repair and response pathways or cell cycle control. Mutagenic analysis may be 
followed to map the domains of Rad18 protein to other novel functions or interactions that 
may be thus identified. 
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5. Materials 
 
 
5.1. Chemicals and reagents 
All Chemicals and materials used were purchased from the following companies: 
Applied Biosystems (Foster City, USA), BD Biosciences (Heidelberg), Biochrom 
(Berlin), BioRad (Munich), Bruker Daltonik (Bremen), Costar (Bodenheim), Dianova 
(Hamburg), Eppendorf (Hamburg), Fluka (Taufkirchen-Munich), GE Healthcare Europe 
(previously Amersham Biosciences, Freiburg), Greiner (Frickenhausen, Nuertlingen), Integra 
Biosciences (Fernwald), Invitrogen (Karlsruhe), Kodak (Rochester, USA), Labor Schubert & 
Weiß GmbH (Munich), Laborteam K+K (Munich), MBI-Fermentas (St. Leon-Rot), Merck 
(Darmstadt), Millipore (Bedford, USA), MP Biomedicals (Eschwege), NEB (Schwalbach), 
neolab (Heidelberg), Nunc (Wiesbaden), PAA (Pasching, Austria), Perbio Science (Bonn), 
Promega (Mannheim), Qiagen (Hilden), Roche Applied Science (Mannheim), Roth 
(Karlsruhe), Sigma-Aldrich (Taufkirchen-Munich), Stratagene (Amsterdam, Netherlands). 
 
 
 
5.2. Equipments 
Biological incubator shakers    New Brunswick Scientific 
Electrophoretic apparatus    BioRad 
Eppendorf table centrifuge    Eppendorf 
Developer Machine X-OMAT   Kodak 
Electroporation equipment Gene Pulser II  BioRad 
Cell culture CO2 Incubator    Heraeus Christ Instruments 
PCR cycler      Biometra 
Light Cycler      Roche 
Photometer      Eppendorf 
Laminar sterile hood     Haereus Christ Instruments 
Centrifuges      Eppendorf; Sorvall; Beckman; Hettich 
Spectrophotometer     Eppendorf 
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5.3. Kits 
All kits were used according to manufacturer’s instructions. 
GFX Micro Plasmid Prep Kit (Amersham Biosciences, Freiburg) 
Jet Star 2.0 Plasmid Purification Kit (Genomed, Löhne) 
QIAgen Gel Extraction Kit (Qiagen, Hilden) 
QIAgen PCR Purification Kit (Qiagen, Hilden) 
RNeasy Kit (Qiagen, Hilden) 
1st Strand cDNA Synthesis Kit (Roche Applied Science, Mannheim) 
FastStart DNA Master SYBR Green I Kit (Roche Applied Science, Mannheim) 
DC Protein Assay (BioRad, Munich) 
ECL Kit (Amersham Biosciences, Freiburg) 
 
 
5.4. Bacteria 
The Escherichia coli strain, DH5α was used for cloning. 
Genotype: F-, φdlacZ Δ M15, endA1, recA1, hsdR17 (rk-, mk-), supE44, thi-1, gyrA96, 
relA1, Δ(lacZYA-argF)U169, λ- 
 
 
5.5. Enzymes 
Table 5: List of Enzymes used 
Enzymes and buffers Supplier 
T4-DNA-Ligase and 10x ligase buffer Roche Applied Science 
Restriction enzymes & (10x) reaction 
buffers 
MBI-Fermentas, New England Biolabs and 
Roche Applied Science. 
Taq-Polymerase and buffer Roche Applied Science and Qiagen 
TurboPfu-Polymerase Stratagene 
acTEV Protease Invitrogen 
Trypsin Gold Promega 
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5.6. Antibodies 
Table 6: List of primary antibodies 
Primary 
reagents Dilution Host Reactivity Source 
AID 5G9 1:5 Rat Hu, Ch E.Kremmer, Helmholtz Zentrum 
HA 3F10 1:100 Rat epitope E.Kremmer, Helmholtz Zentrum 
RPA RBF 4E4 1:5 Rat Hu, Ch E.Kremmer, Helmholtz Zentrum 
GAPDH 1:5000 Mouse Hu, Ch Abcam 
Tubulin 1:1000 Rabbit Hu, Ch Abcam 
PCNA 1:10000 Mouse Hu, Ch Abcam 
Ubiquitin 1:2000 Mouse Hu, Ch Santa Cruz 
p53 1:500 mouse Hu, Ch Santa Cruz 
Rad6 1:5000 Rabbit Hu, Ch Bethyl Laboratories 
Ubc13 1:1000 Mouse Hu, Ch Abcam 
JIF-1 (QM) 1:500 Rabbit Ch Santa Cruz 
RPS3a 1:1000 Mouse Hu, Ch Abnova 
RBBP4 1:1000 Mouse Hu, Ch Abcam 
Rad18 
Rad18 
1:1000 
 
Mouse 
Rabbit 
Hu 
Hu 
Abcam 
Bethyl laboratories; used for IPs 
pJNK 1:1000 Rabbit Hu, Ch Abcam 
pAkt 1:1000 Rabbit Hu, Ch Cell signalling 
PAP 1:2000 Rabbit – Sigma; for detection of TAP tag 
Hu – Human; Ch – Chicken 
 
Table 7: List of secondary antibodies 
Secondary reagents Dilution Host Antigen Source 
anti-mouse-HRP 1:5000 goat Mouse Promega 
anti-rat-HRP 1:5000 goat Rat Jackson Immuno Research 
anti-rabbit-HRP 1:3000 goat Rabbit Cell Signalling 
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5.7. Oligonucleotides 
Table 8: Primers for qRT-PCR 
Primer Name Nucleotide sequence (5´ 3´) 
SGS-Rad18-SFor1 GAT GTA GCT AAC CGT TGT CTT C 
SGS-Rad18-SFor2 GGT CTG GCA GGA ACA GAT TGG 
SGS-Rad18-SFor5 CTG CCA TAG GAT TGC CAG CAG G 
SGS-Rad18-SRev1 CTG CTG AGA CAG CTG TCC AG 
SGS-Rad18-SRev4 GGC AAA GAC GCA GGA GTC TTG G 
SGS-Rad18-SRev5 CTC TTC ACT AGC TCA TCT AAC GTC 
SGS-Rad18-SRev6 GTA TCC AAG ACC AAC TGG ACC AG 
SGS-NTAP-SFor1 GCT AAA TGA TGC TCA GGC GCC G 
C-TAP1 GTA TCG GCA GAG TCG TCG GTT G 
SGS-AID-SFor1 GGG AAG TAC AGA GCA TTC CAC G 
SGS-AID-SRev1 GAG GTG AAC CAT GTG ATG CGG 
SGS-HPRT-SFor1 TAT TGT TGG AAC TGG AAG GAC AAT G 
SGS-HPRT-SRev1 ACT CAC TGC TGT ATA TAT TCA TCA G 
 
Table 9: Oligonucleotides used for cloning the Rad18-HA-TAP fusions 
Primer 
Name 
Nucleotide Sequence (5´ 3´) Enzyme 
SGS-Rad18-
For3 
GGG ACTAGT GAATTC GGG TCG CC ATG GCC CTG G 
SpeI, 
EcoRI 
SGS-Rad18-
Rev2 
CCC GGATCC TGCATAGTCCGGGACGTCATAGGGATA C 
GCGGCCGC GCT CTT CTT CCT CTT GCT CCT G 
BamHI, 
NotI 
SGS-Rad18-
For4 
GGG CCAGCACAGTGG GG 
TATCCCTATGACGTCCCGGACTATGCA ATG GCC CTG 
GCG CTG CCC G 
BstXI 
SGS-Rad18-
Rev3 
CCC GTC GAC CCT ACA CCC AGT GGC TCT GC SalI 
SGS-Rad18-For3 and SGS-Rad18-Rev2 was used for CTAP cloning 
SGS-Rad18-For4 and SGS-Rad18-Rev3 was used for NTAP cloning 
Underlined – restriction sequence used for the cloning of the PCR fragment into the pZome 
expression vector; Italicised – HA tag sequence; Bold – Start codon 
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Table 10: Oligonucleotides used for cloning the Rad18-HA construct 
Oligo Name Nucleotide Sequence (5´ 3´) Enzyme 
SG-Ct-Oligo1 GATCC TAG GGGCCC G ApaI 
SG-Ct-Oligo2 TCGAC GGGCCC CTA G ApaI 
Oligo1 and Oligo2 – complementary strand sequences that generate BamHI (5‟) and SalI (3‟) 
restriction overhangs upon annealing.  
Underlined – Apa1 Restriction site for testing insertion after cloning; Bold – Stop codon 
 
5.8. Plasmids 
The plasmids pZome-1C carrying the C-terminal TAP tag and pZome-1N carrying the 
N-terminal TAP tag were obtained from the company Cellzome, Heidelberg, Germany. The 
NTAP-AID construct in pCAG (pST 8-2), the AID-CTAP construct in pZome (pST 7-2) and 
pCAG (pST10-10) vectors were available from Stephanie Tobollik, Helmholtz Zentrum 
Muenchen (Tobollik 2007). 
 
5.9. Cell lines 
Table 11: Source and particulars of the cell lines used 
Cell line Source Remarks 
Chicken B-cell line – DT40 
Cre1 
H. Arakawa, 
Neuherberg 
The “wild type” DT40 cells 
Rad18
-/-Δ
 
B. Jungnickel, 
Grosshadern 
Rad18 knockouts in Cre1 wt cells in which the resistance 
cassettes were removed by tamoxifen induced Cre recombinase 
Ψ- 
OR 
Ψ- AID-/-® 
H. Arakawa, 
Neuherberg 
Pseudo-V gene knockout => Ig gene conversion defective; 
endogenous AID knockout and exogenous AID-GFP expression 
(puromycin resistant) 
Ψ- AID-/- 
B. Jungnickel, 
Grosshadern 
The loxP flanked AID expression cassette was removed by 
Tamoxifen induced Cre recombinase by Christina Glon 
Ψ- Rad18-/- 
B. Jungnickel, 
Grosshadern 
Rad18 knockout, Puromycin + Blasticidin resistance cassettes 
present 
Ψ- Parental 
H. Arakawa, 
Neuherberg 
A subclone of Ψ- cells. Pseudo-V gene knockout with 
endogenous AID knockout and exogenous AID expression 
(puromycin resistant) 
Ψ- PCNA 
K164R 
H. Arakawa, 
Neuherberg 
PCNA mutant + exogenous AID expression (puromycin 
resistant) 
Human B-cell line: 
Raji ATCC 
J. Bachl, 
München 
Burkitt Lymphoma cell line, EBV-positiv 
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5.10. Softwares 
 
The following software programs were used: 
Sci Ed Central (Clone Manager 6) Sequence analysis 
Microsoft office 2003 Data processing and compilation 
Adobe Photoshop 6.0 Image processing 
Chromeleon
®
 nano-HPLC 
μCarrier (microcarrier) Probot Microfraction Collector 
GPS Data Explorer 2.0 MS/MS-analysis 
MASCOT Search engine 
NCBI Gallus Protein database 
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6. Methods 
6.1. Standard methods 
Standard methods were performed according to Sambrook and Russel (2001) or 
according to the manufacturer protocol. 
 
 
6.2. Cloning of the Rad18-HA-TAP fusions 
Rad18-HA-CTAP clone (SG-RC1): 
The Rad18 cDNA was amplified with the SGS-Rad18-For3 and SGS-Rad18-Rev2 
primers to add an HA tag to the C- terminus of the protein. Then the PCR fragment and the 
pZome-1C vector (obtained from Cellzome, Germany) were each restriction digested with 
SpeI and BamHI. The PCR fragment was ligated into the pZome vector that already carried 
the TAP tag, at 4°C overnight in the presence of T4 DNA ligase and its appropriate buffer. 
The ligated vector was sequenced to ensure sequence fidelity. 
NTAP-HA-Rad18 clone (SG-RN1) 
The Rad18 cDNA was amplified with the SGS-Rad18-For4 and SGS-Rad18-Rev3 
primers, to add a HA tag to the N- terminus of the protein. Then the PCR fragment and the 
pZome-1N vector (obtained from Cellzome, Germany) were restriction digested with BstXI 
and SalI. The PCR fragment was ligated into the pZome vector that already carried the TAP 
tag, at 4°C overnight in the presence of T4 DNA ligase and its appropriate buffer. The ligated 
vector was sequenced to ensure sequence fidelity. 
 
6.3. Cloning of Rad18-HA (R18-HA1) 
The cloning was carried out by removing the TAP tag from the SG-RC1 vector by 
restriction digestion with BamHI and SalI. The oligos SG-Ct-Oligo1 and SG-Ct-Oligo2 were 
annealed by mixing 250μM of the oligo at equimolar concentration and subjecting it to 95°C 
for 5 mins followed by gradual cooling to room temperature (RT). The BamHI and SalI 
digested vector was then ligated with the annealed oligo at 4°C overnight in the presence of 
T4 DNA ligase and its appropriate buffer, to generate the Rad18-HA (C-terminal) fusion 
expressed from the pZome vector. 
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6.4. RNA isolation and cDNA synthesis 
The total mRNA from approximately 3x10
6
 cells was isolated using the RNeasy Kit 
(Qiagen, Hilden) according to the manufacturer's specifications. A maximum of 1μg total 
RNA was reverse transcribed using the 1st strand cDNA Synthesis Kit (Roche Applied 
Science, Mannheim, Germany) in order to generate the cDNA. The p-oligo(dT) 15 primer and 
reverse transcriptase enzyme were used for this reaction. The cycle conditions were: 
annealing of primers for 10 minutes at 25°C, reverse transcription at 42°C for 1 hour, 
denaturation of the enzyme at 99°C for 5mins. The cDNAs obtained were stored at -20°C and 
used whenever required for qRT-PCR reactions. The qRT-PCR in the Light Cycler was 
carried out according to the instructions from Roche. 
 
6.5. SDS PAGE & western blot analysis 
Approximately 3x10
6
 cells were washed with PBS and pelleted. The pellets were lysed 
using 2x Laemmli buffer (Laemmli 1970). The protein contents of these cell lysates were 
estimated using the DC protein assay from Bio-Rad (Munich), according to the 
manufacturer‟s instructions. 60μg of protein per lane were subjected to electrophoresis in 12% 
SDS-polyacrylamide gels and transferred on to a Polyvinylidene difluoride (PVDF) 
membrane. After transfer, the membrane was blocked with 5% skim milk in PBS and 
incubated with the appropriate primary antibody overnight at 4°C. The membrane was then 
washed with PBS and incubated with the appropriate secondary antibody for 3h at RT. The 
membrane was again washed in PBS before treating with the Chemiluminescence reaction 
using the ECL or Advance
TM
 ECL Western Blotting Detection Kits (both, GE Healthcare, 
Freiburg) to visualise the signal of the proteins probed. Note that the PAP reagent alone did 
not require probing with secondary antibody. 
 
6.6. Native PAGE & blotting 
2x10
7
 cells were resuspended in 100µl lysis buffer (50 mM Tris-HCl [pH 8.0], 1% 
IGEPAL, 150mM NaCl and protease inhibitors - added fresh) and vortexed thoroughly for 
about 5 seconds. The mixture was incubated on ice (at 4°C) for 20-30 mins with sporadic 
vortexing. After incubation, the DNA was disrupted by ultrasonication. The samples were 
vortexed thoroughly for about 5 seconds and centrifuged for 10mins with 16400rpm (max. 
rpm) at 4°C. The lysate supernatant was mixed 1:1 with 2x sample buffer (125 mM Tris-HCl 
[pH 6.8], 30% glycerol and 0.02% bromophenol blue). 50ul of this sample was loaded in an 
SDS-free polyacrylamide gel (6.5%) and electrophoretic separation was performed in the 
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absence of SDS at 4°C. The Blotting was carried out in the absence of methanol with the 
same 1x buffer as the running buffer (14.4grams Glycin and 3.02grams Tris dissolved in 1 
litre Millipore water) for 1.5hours and 450mA at 4°C. The membrane was blocked in 5% milk 
and probed by chemiluminiscence for the fusions with the PAP reagent as described before in 
section 5.2.5. 
 
6.7. TAP extraction of GOI-TAP fusions 
All steps were carried out on ice with all buffers and tubes pre-chilled and everything 
keratin free. 2x10
9
 cells (for DT40 Rad18-NTAP) and 1x10
9
 cells (for DT40 Rad18-CTAP) 
were pelleted and resuspended in 5ml extract buffer (30mM Tris-HCl, 150mM NaCl, 10μM 
ZnCl2, 1.5mM MgCl2, 10% Glycerol, 1mM β-ME, 0.5M PMSF and complete –E) and cell 
clumps were dislodged by homogenizing in the DOUNCE homogenizer by moving the pestle 
up and down very slowly and gently for 5 times. To the cell suspension, 5ml lysis buffer 
(30mM Tris-HCl, 150mM NaCl, 10μM ZnCl2, 1.5mM MgCl2, 10% Glycerol, 1mM β-ME, 
0.5M PMSF complete –E and 0.5% IGEPAL) was added and homogenized as before for 10 
times. The extract was centrifuged for 1hr, at 4°C, with a minimum of 13,000rpm. The 
supernatant was used subsequently for TAP or for CoIPs or stored at -20°C until use. 
 
6.8. Tandem Affinity Purification 
Ig Binding 
450µl Ig beads for each extract were washed in 5ml IPP150 buffer (10mM Tris-HCl, 
150mM NaCl, 10µM ZnCl2, 1% IGEPAL) three times by centrifugation at 600rpm 4°C, 1 
min. 10ml of the lysate supernatant of the TAP extract were added to the washed Ig beads and 
incubated with rotation overnight at 4°C. 
TEV Cleavage and Elution 
The beads that were incubated overnight with the TAP lysate supernatant were 
centrifuged for 2 minutes at 600rpm, 4°C and the supernatant was removed. The beads were 
washed 3 times with 10ml IPP 150 buffer and the final wash was made with 10ml of the TEV 
cleavage buffer (10mM Tris-HCl, 150mM NaCl, 10µM ZnCl2, 1% IGEPAL, 0.5mM EDTA, 
1mM β-ME) and the supernatant was removed as much as possible at this step. The 400µl 
beads were gently resuspended in the remaining volume of the TEV Cleavage Buffer and 
transfered into labeled luerlock columns (small), with filter, lid and stopper. Again 400µl of 
TEV cleavage buffer was added to the transferred beads followed by 10µl TEV protease 
enzyme (100 units). This was then incubated with moderate rotation for 3 hours at 15°C. The 
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TEV eluate is collected by placing the column in eppendorf tubes after removing the stopper 
followed by centrifugation at 1000 rpm for 1 min, 4°C. 
Calmodulin Binding 
The BioRad columns were equilibrated with 2ml CB buffer (10mM Tris-HCl, 150mM 
NaCl, 10µM ZnCl2, 1% IGEPAL, 1mM Mg Acetate, 1mM Imidazole, 2mM CaCl2, 10mM β-
ME) on ice. 400µl of Calmodulin resins (slurry) were washed 3 times with 500µl CB buffer. 
3ml CB buffer, 800µl TEV eluate + 200µl TEV cleavage buffer (making TEV eluate to 1ml) 
+ 3µl CaCl2 were taken in the BioRad columns. To this, 400µl of the washed Calmodulin 
resin was added and closed to incubate on a roller at 4° C room for 3 hours. 
Calmodulin Elution 
After incubation, the CB flow through was collected and the CB resins were washed 
three times with 10ml CB buffer by allowing the buffer to flow through the column placed 
over a collecting falcon tube. The stoppers of the columns were then closed and 500µl of 
Calmodulin Elution buffer (10mM Tris-HCl (pH 8), 150mM NaCl, 1% IGEPAL, 1mM Mg 
Acetate, 1mM Imidazole, 2mM EGTA, 10mM β-ME) was added to the resins and incubated 
for 15 minutes on ice. After 15 minutes, the CB eluate was collected in pre-lubricated 
eppendorf tubes and this elution step was repeated to maximise the recovery. All fractions 
were stored at -20°C until further use. 
 
6.9. TCA protein precipitation 
An equal volume of 20% (w/v) TCA was added to the protein samples, mixed by 
vortexing and incubated on ice for 20mins. The proteins were pelleted in a cooling centrifuge 
at maximum speed for 10mins. The supernatant was removed and the protein pellet was 
washed with 200μl ice-cold acetone for three times. The pellets were dried at RT and 
dissolved in the sample buffer used for SDS PAGE by incubating at 70°C in a shaker for 20 
mins at 550rpm. The samples are stored -20°C 
 
6.10. Silver stain analysis 
The silver staining of using SDS-polyacrylamide gel electrophoresis separated proteins 
was carried out after Blum (Blum et al. 1987). 
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6.11. In-Gel Trypsin Digest 
The protein sample was loaded in the NuPAGE gel system (Invitrogen) and subjected to 
electrophoresis for about 1cm length. The gel portion containing the sample was cut out and 
divided into two fractions. Each fraction was then cut into smaller pieces and transferred to 
labelled keratin-free 500µl eppendorf tubes. The gel pieces were immersed in 50µl ABC 
Buffer (50mM NH4HCO3 in 30% acetonitrile) and incubated for 5min at 37°C. Then the 
buffer was removed and discarded. This wash was carried out 3-4 times. The alkylation of the 
proteins was done by incubating the gel pieces in 50µl DTT solution (3.5mg in 500µl 
deionised water) for 15min at 55°C. Then, the sample was allowed to cool and then incubated 
with 50µl Iodoacetamide solution (18.6mg in 1ml deionised water) in the dark for 15min at 
RT. Then the gel pieces were washed for at least 3 times with ABC buffer (mandatory). 
The gel pieces were then incubated with 100µl of 100% acetonitril for 15min at RT. The 
acetonitrile was then removed and this step was repeated until all the gel pieces turned 
completely white and shrunken in size. After this, the remaining acetonitrile was completely 
vaporized at RT or at 37°C with the lids of the eppendorf tubes open. To the dried gel 
“crumbs” 1µl of the trypsin digest solution (5µl Trypsin 0.03µg/µl mixed fresh with 180µl of 
the 10mM NH4HCO3 digest buffer) was added directly on the gel and in about 5mins, the gels 
swelled back taking in all the digest solution. The digest solution was added until they are 
completely immersed in the solution within the range of 4µl to maximum of 10µl. This 
reaction mix was incubated overnight at 37°C. After the overnight digestion, the excess digest 
solution (if any) was collected in a new labelled siliconized eppendorf tubes. Then, 10µl of 
the elution buffer (80% Acetonitrile/ 1%TFA) was added to the gel pieces and sonicated for 
5min in an ultrasonication bath. The samples were then centrifuged shortly and the eluate was 
collected. The elution step was repeated until the gel pieces became white and shrunken 
again. The eluate was lyophilised in the SpeedVac lyophiliser. Just before using for the 
HPLC, the peptide pellet was redissolved in 19µl 0.1% TFA for each of the two fractions of 
the samples and 9µl of each was pooled for the HPLC. 
 
 
6.12. Reverse phase Nano-Liquid Chromatography 
The peptides digested by the in-gel trypsin digest method were separated on a reverse-
phase chromatography. The stationary phase of the column consists of porous silica particles, 
coated with 18-alkyl chain. The peptides are absorbed on the hydrophobic surface of the 
column and are eluted with an increasing gradient wash with acetonitrile (ACN). The 
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separation was performed by the Ultimate HPLC unit from Dionex. The flow rate of the 
HPLC buffers (buffer A: 5%ACN /0.1%TFA in water, buffer B: 80%ACN / 0.08% TFA in 
water) was 200nl/min. The linear gradient from 50 to 100% buffer B was used for the 
separation of the peptides for about 82min, followed by a 6-minute-long washing step with 
100% buffer B. By using a pre-column with the same carrier material, the salt that may be 
present in the sample was removed before further mass spectrometric analysis. After the 
separation, the absorption of peptides was detected in a UV detector at a wavelength of 214 
nm. The peptides that were separated were collected along with the matrix by an automated 
PROBOT microfraction collector according to the instructions given by the manufacturer. 
The PROBOT mixed the peptide eluating from the LC with a matrix solution (5mg/ml a-
cyano-4-hydroxy cinnamic acid [CHCA] in 0.1% TFA, 70% ACN) in the ratio of 1:4 and 
distributed the mixture into 275 fractions, with a retention time of 30 seconds per fraction on 
a MALDI target. The samples were then ready for the MALDI analysis. 
 
 
6.13. MALDI TOF-TOF 
The device used was the 4700 proteomic analyser that is equipped to perform MALDI-
TOF/TOF (matrix assisted laser desorption/ionization time of flight/time of flight) analysis 
(Applied Biosystems, Foster City, USA). During the analysis, peptides with masses 800 to 
5500 Daltons (Da) were analyzed. The masses of individual peptides were extrapolated based 
on the time taken for them to travel through a defined path in high vacuum (Time of Flight - 
TOF). The speed of flight of the peptide ions is directly proportional to 1/√m (where m = 
mass of the ion). This implies that the heavier ions require a longer time of flight and the mass 
of the charged ions can be accurately estimated based on the TOF. The tandem mass 
spectrometry or MS/MS was applied for the identification of peptides from a peptide mixture 
during which a particular peptide identified by the first MS analysis was identified in the 
second MS analysis and subjected to collision in a gas chamber. This leads to the 
fragmentation of the peptides into individual fragments. 
For a given peptide the fragmentation pattern is predictable and this is achieved by the 
division of the amide linkages between the various amino acids of the peptide. The ions are 
created as a b-ion, when the fragmentation occurs at the N-terminus of the peptide bond and 
as a y-ion, if the fragmentation occurs at the C-terminus. Besides these, other types of 
fragmentations also occurs, namely a, c, x and z ions according to their positions from the 
amide bond. The information about the fragmentation pattern for a given peptide was used by 
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the MASCOT software to identify the peptide mass and sequence. The parameters used for 
the analysis of the samples were as follows: The LASER was used with a frequency of 200Hz 
and a wavelength of 355 nm. For an MS analysis, the number of LASER shots per spectrum 
was 2500 and for the subsequent MS/MS optics, the number of shots per spectrum was 
increased to 4500 and the LASER intensity was increased by 200 units compared to the MS 
optics. The 4700 analyser software generates the list of masses and automatically selects the 
peptide precursors for MS/MS measurement. The mass was calibrated based on the peptide 
standard (Bruker Daltonik, Bremen). The resulting MS/MS spectra were loaded in the GPS 
Explorer 2.0 (Applied Biosystems, Foster City, USA) and a search against an appropriate 
protein database (SwissProt/NCBI-entire/NCBI Gallus) was made with the help of an 
integrated MASCOT search algorithm. 
With the MASCOT search engine, a probability-based molecular weight search is 
possible (the probability model is not published in detail). The parameters for the MASCOT 
search were set as follows: the enzyme used was selected as trypsin; Carbamide methylation 
was fixed and the methionine oxidation was specified as variable. The database was selected 
as NCBI Gallus, the minimum peptide rank was set at 3, the maximum peptide score was set 
to 10 and the ppm was set to 100. The GPS Explorer software analysis assigned two scores of 
significance, the best ion score and the total ion score. The best ion score is the highest score 
of among all the peptides identified for a given protein and the total ion score is the score 
obtained by the sum of all the scores for all the peptides identified for a protein. The proteins 
were sorted according to the total ion score C.I. % (confidence interval %), a value calculated 
by the MASCOT analysis software based on the best ion scores of the peptides identified for 
the protein. The software assigned this score for every protein identified by taking into 
consideration the best ion score, the total ion score and the nature of the database and so on. A 
huge un-curated database such as NCBI was considered with more stringency than the curated 
ones like Swissprot. A protein with a total ion score C.I. % of ≥95% was considered 
significant. The proteins that were considered for further analysis were not only significant 
(≥95%) but those that met the following additional criteria: 1) those that were identified in 
more than one sample or purification with a significant score and 2) identified with a reliable 
y and b MS/MS fragmentation for a given peptide. 
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6.14. Co-immunoprecipitation in the Rad18-HA-TAP DT40 cells 
The immunoprecipitation in the Rad18-HA-TAP clones was carried out by first 
removing the protein A part of the TAP tag that might interfere with the IP. For this, TAP 
extract of the cells was set up for overnight Ig binding as per the TAP protocol. After 
overnight incubation, the beads were centrifuged with 5000rpm at 4°C for 1min and the 
supernatant was removed as “IgB Supt”. The beads (about 50μl) were then washed 3 times 
with 500μl of the TAP extract Buffer (by adding 500μl buffer, followed by centrifugation and 
discarding the supernatant wash). Then the bound protein was eluted by TEV protease 
cleavage step (as described previously) and the TEV eluate was incubated with the bait 
antibody and protein G beads with the appropriate controls. After overnight incubation, the 
beads were pelleted and the supernatant was collected as the IP supernatant. The pellets were 
then washed with low-salt or high salt buffer for 5 times with 500μl lysis buffer, followed by 
centrifugation and discarding the supernatant (wash). The pellet was then processed with 2x 
sample buffer and analysed by immunoblotting. 
 
 
6.15. Endogenous co-immunoprecipitation in Raji cells 
The cell number of 6x10
6
 cells was used for each IP which as extracted as per the TAP 
extraction protocol described earlier. The bait antibody, with and without lysate, isotype 
matched antibody with lysate and a sample with only lysate and no antibody (null) were set 
up in duplicate so that one set would be washed with low salt (150mM of NaCl) and the other 
with high salt (300mM NaCl). 500μl of the TAP lysate was added to the protein G beads that 
were preincubated for 1h with 5μg of the antibody. These were incubated with rotation for 3-4 
hours at 4°C. After incubation, the beads were centrifuged with 5000rpm at 4°C for 2 min. 
The supernatant was removed and the pellet was washed 5 times with low salt or high salt 
buffer whichever was appropriate. The washed pellet (about 50ul) is the immune precipitate 
with the beads and it was processed for western blot analysis. 
 
 
6.16. Cell culture 
All cell culture methods were carried out under sterile conditions in the laminar hood 
(Heareus Christ instruments, Dusseldorf) with sterile glass or plastic pipettes. The cells were 
incubated (Heareus Christ instruments, Dusseldorf) at 5% CO2, 95% humidity and 41°C for 
chicken DT40 cells and 37°C for the Raji human cells in culture. 
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Table 12: Chicken Media for the DT40 cell culture: 
Volume 
added 
Components of DT40 cell culture media 
Final 
concentration 
500ml RPMI 1640 Medium (Invitrogen, Karlsruhe) - 
50ml FCS (Biochrom KG, Berlin und PAA, Pasching, Austria) 10 % 
5ml Penicillin (Invitrogen, Karlsruhe) 100 U/ml 
5ml Streptomycin (Invitrogen, Karlsruhe) 100 µg/ml 
5ml Glutamine (200 mM) (Gibco BRL, Schottland) 2 mM 
5ml Sodium Pyruvate (100 mM) (Gibco BRL, Schottland) 1 mM 
50µl β-mercaptoethanol (1M) 10 mM 
5ml Chicken serum (Sigma) 1% 
The media for Raji human cells was prepared with the above ingredients except the β-
mercaptoethanol and chicken serum. 
 
 
6.17. Transfection of DT40 cells 
About 25-50µg (about 50µl) of plasmid DNA was linearized outside of the genes of 
interest by digestion with an appropriate restriction enzyme in 500µl total volume for 3-5 
hours at the appropriate temperature for the enzyme. Then 1ml of 100% ethanol was added to 
precipitate the DNA overnight in -20°C. The cells were seeded in a healthy growth density. 
The overnight precipitated DNA was centrifuged for 20min 14000rpm at 4°C and washed 
with 1ml 70% ethanol. The supernatant was discarded and the pellet was dried under the 
hood. The dried pellet was resuspended in 500µl sterile PBS solution. 1x10
7
 cells where 
washed and resuspended in 300µl of PBS and dissolved DNA was added to the cells, mixed 
and transferred into a pre-chilled electroporation cuvette. The cell-DNA mix was incubated on 
ice for 10min and the electroporated using a BioRad electroporator set at 25µF and 550 volts 
and kept on ice for another 10min. The cell/DNA solution was added to 10ml of chicken 
medium and 100µl was distributed into each of the wells of a 96-well microtiter plate. The 
cells were selected with 100µl of selective medium (containing twice the final concentration 
of the drug) added to each well after an overnight incubation for the cells to recover. Drug 
resistant colonies were retrieved after about ten days in the incubator. 
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6.18. Colony Survival assay for DT40 using chemical agents 
The colony survival assay was carried out exactly as described earlier (Simpson and 
Sale 2006). 
 
 
6.19. Nuclear/Cytoplasmic Fractionation 
5x10
6
 cells were washed in PBS and resuspended in 90µl Mendez A-Buffer (10mM 
Hepes pH 7.9, 10mM KCl, 1.5 mM MgCl2, 10% Glycerol, 0.34M Sucrose, 0.5mM DTT, 
Proteinase Inhibitors). 30µl of this fraction was aliquoted as “Total Extract”. Then 40µl 
Mendez A-Buffer was mixed with 0,4µl 10% Triton-X 100 (1:100) and 40 µl Mendez A/ 
Triton X (final: 0,04% Triton-X 100; 1:250) was added to the remaining 60µl cell sample. 
The mix was incubated on ice for 10 mins and centrifuged for 4 min; 1300 rpm; 4°C (step A). 
The pellet and the supernatant were separated and each was processed further separately. The 
supernatant was centrifuged for 1h at full speed (ca.13000 rpm) and 4°C and the supernatant 
was taken into a clean eppendorf tube as the cytoplasmic fraction. The pellet from Step A is 
washed with 150µl Mendez A with centrifugation for 4 min; 1300 rpm; 4°C. The supernatant 
was discarded and the pellet is dissolved in 100µl Mendez A buffer as the nuclear fraction. 
 
 
6.20. DNA damage induced activation of the JNK/AP1 pathway 
The cells in a healthy growing density (2.5x10
5
/ml) were seeded using 4.5x10
7
 cells in 
150ml media without MMS and left overnight. The following day, the cells were counted to 
verify that they have been proliferating before treating with MMS. The cells were adjusted to 
an equal total number (9x10
7
) just before starting the assay in case they were at different 
numbers provided they had doubled and look healthy. The total volume of the culture was 
made up to 180ml with fresh media and 20ml of this culture was pelleted for the untreated 
protein pellet. An appropriate amount of MMS that equals 1mM final concentration in the 
remaining 150ml culture was added and mixed thoroughly by pipetting. The cells were 
harvested at 2, 4, 6, 8, and 10h incubation time points. The cell pellets were extracted for total 
protein and analysed by western blot analysis with a phospho-JNK (pJNK) antibody. 
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Appendix 
CONTENTS: 
 
Appendix 1 – MASCOT analysis of TAP of AID fusions 
Analysis with swissprot, NCBI-entire and NCBI Gallus databases 
Exp. No Sample Name 
TAP3 Tf2/3B: NTAP-AID 
TAP3 Tf7/1-16: TAPalone 
TAP10 pST10-10B: AID-CTAP 
TAP10 pSK1-1A: TAPalone 
 
 
Appendix 2- MASCOT analysis of TAP of Rad18 fusions 
Analysis with NCBI Gallus database 
Exp. No Sample Name 
TAP8(12) Tf9/1-1: Rad18-HA-CTAP 
TAP8(12) Tf9/3-3: NTAP-HA-Rad18 
TAP8(12) Tf7/1-16: TAPalone 
TAP10 Tf9/1-1: Rad18-HA-CTAP 
TAP10 Tf9/3-3: NTAP-HA-Rad18 
TAP10 Tf7/1-16: TAPalone 
 
 
 
KEY: 
 
Tf# – Transfection experiment number 
TAP# – TAP experiment number 
bold font – Bait protein; known and interesting interaction partners 
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IRES Internal ribosomal entry site 
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l Litre 
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M molar (Mol/Litre) 
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mg milligram  
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MMR mismatch repair 
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MS mass spectrometry  
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NHEJ non-homologous end-joining 
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PAGE polyacrylamide gel electrophoresis 
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PCR polymerase chain reaction 
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PCNA
(Ubi)n
 Polyubiquitinated PCNA 
pH negative logarithm of the hydrogen ion concentration 
POI protein of interest 
Pol polymerase 
PVDF Polyvinylidene difluoride 
Py ori polyoma origin of replication 
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qRT-PCR quantitative real time polymerase chain reaction 
R Arginine 
RNA Ribonucleic acid 
RNase Ribonuclease  
RPA Replication protein A 
rpm rotations per minute 
RT room temperature 
RT-PCR reverse transcription – polymerase chain reaction 
Sec seconds 
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SHM somatic hypermutation  
S-Region switch region  
SSB single strand break 
SV40 Simian virus 40 
T thymine 
TAP tandem affinitiy purification 
TAPalone the cell clone expressing the TAP tag alone 
TEMED N,N,N‟,N‟- Tetramethylendiamine 
TEV Tobacco etch virus 
TEV E eluate obtained after TEV protease cleavage 
TLS translesion synthesis 
TOF time of flight 
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U uracil 
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UV ultraviolet radiation 
V volt 
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w/v weight per volume 
 
 113 
Index of Figures 
FIGURE# FIGURE TITLE Page # 
Figure 1 Coordination of the cell cycle checkpoints with DNA damage processing 3 
Figure 2 Adaptive genetic alterations in the Ig heavy chain locus 7 
Figure 3 Model for repair of AID-induced lesions by Somatic Hypermutation, Class 
Switch recombination and Gene conversion (Rada et.al. 2004) 10 
Figure 4 Targeting of Somatic Hypermutation by locus-specific differential 
processing of AID-induced lesions 11 
Figure 5 The Rad6 Pathway in yeast 13 
Figure 6 Schematic representation of the functional domains and ligand-interacting 
regions of human Rad18 Source: Notenboom et al. 2007. 18 
Figure 7A A schematic representation of the TAP Tag 20 
Figure 7B An overview of Tandem Affinity Purification (TAP) 20 
Figure 8 An overview of the approach to study protein interaction networks in DT40 
cells 24 
Figure 9 A Schematic depiction of the exogenous expression vectors tested 25 
Figure 10 Expression levels of AID-TAP fusions in DT40 cells 27 
Figure 11 Analysis of tandem affinity purification of AID-TAP fusions 29 
Figure 12 The chromatogram of the nano-LC separation of AID-TAP fusion peptides 31 
Figure 13 Expression levels of Rad18-HA-TAP fusions 35 
Figure 14A Native PAGE of Rad18 fusions and TAPalone  37 
Figure 14B Nuclear/cytoplasmic localisation of Rad18-HA-TAP fusions and TAPalone 
control 37 
Figure 15 Survival curves of the methylcellulose colony survival assay with increasing 
doses of cisplatin (in μM) 38 
Figure 16 Western blot analysis of tandem affinity purification of Rad18-HA-TAP 
fusions 39 
Figure 17 Silver stain analysis of TAP method of Rad18-HA-TAP fusions 40 
Figure 18 The chromatogram of the nano-LC separation of peptides of Rad18-HA-
TAP fusions and TAP-alone. 41 
Figure 19 Co-immunoprecipitation experiments for interesting potential Rad18 
interaction partners 45 
Figure 20 MMS induced activation of the JNK pathway upon stalled replication in 
Rad18 proficient and deficient DT40 cells 47 
Figure 21A The activation of JNK pathway upon DNA damage in the ψ- parental and ψ- 
PCNA K164R mutant DT40 cells 49 
Figure 21B DNA damage induced activation of PI3K/Akt pathway in ψ- wild type vs. ψ- 
Rad18-/- and the ψ- parental and ψ- PCNA K164R mutant DT40 cells 49 
 
 
 
 
114 
Index of Tables 
TABLE# TABLE TITLE Page # 
Table 1 An overview of exogenous and endogenous expression levels determined by 
qRT-PCR 26 
Table 2 A compilation of some of the potential interactions identified for AID-TAP 
fusions when using the NCBI Gallus database for MASCOT search analysis 34 
Table 3 An example of the  primary list of the potential interactions identified for 
Rad18-TAP fusions 42 
Table 4 An overview of the known and interesting potential interaction partners 
identified for the Rad18-HA-TAP fusions 43 
Table 5 List of Enzymes used 65 
Table 6 List of primary antibodies 66 
Table 7 List of secondary antibodies 66 
Table 8 Primers for qRT-PCR 67 
Table 9 Oligonucleotides used for cloning the Rad18-HA-TAP fusions 67 
Table 10 Oligonucleotides used for cloning the Rad18-HA construct 68 
Table 11 Source and particulars of the cell lines used 68 
Table 12 Chicken Media for the DT40 culture 78 
 
 
 
 115 
Acknowledgements 
I would like to offer my sincere thanks to all the people who have been instrumental in 
helping me complete this endeavor. This work would have been impossible without the active 
support of all these people mentioned here (in no particular order). 
I thank my advisor, Berit Jungnickel for giving me the opportunity to pursue my doctoral 
studies in her able guidance and supervision. I thank her for the support she provided 
throughout the period of my study and especially for helping me see my mistakes and learn 
from them. 
I would like to thank Stephanie Tobollik for teaching me the major technical approach of 
this study, besides all the other help in the lab. I am grateful for her patience with my 
annoying questions and for being a good teacher. 
I thank André Kutzera and Sandra Windberg for the valuable technical support they have 
provided for this work. I also owe them a big thank you for helping me improve my spoken 
German language skills. 
I am very thankful to Maren Mierau for the help at the time I landed in Germany and it 
was such a gesture of warm welcome that I will ever remember. I also thank her for the 
troubleshooting we have done together in the lab and for the encouraging words when 
sometimes it did not get us anywhere  
Many thanks to Hanna Scheller and Isin Ertongur, for the enlightening discussions we had 
on both professional and social aspects. I thank them both for helping me understand and 
adjust to the nuances of living in Germany, besides teaching me to bake delicious cakes and 
cookies. I am thankful for the friendship that has developed among us over this period of time 
bridging the cultural and language differences. 
I would like to thank Ines Pfeil for the insightful discussions that I was privileged to have 
with her and for the hand on my shoulder when I was feeling low. (I must mention that I am 
also thankful to Ines for the recipe of my most favorite apple-walnut cake that I still bake over 
and over again). 
I would like to thank Samantha Pill for her co-operation to perform the last experiments 
we did together. I also thank Kerstin, Jutta, Lourdes, Julia, David and Nils. It was wonderful 
to work with them. 
I thank Hakan Sarioglu, Andrea Hartmann, Janine Griese and Ludwig Wiesent for their 
immense support on working with the LC/MALDI devices and MASCOT software. 
 116 
I thank my official PhD supervisor Prof. Dr. Friederike Eckardt-Schupp for her support 
and suggestions. I would like to thank Prof. Dr. Georg Bornkamm, Prof. Dr. Dirk Eick, Dr 
Ulla-Zimber Strobl and Dr. Bettina Kempkes for their valuable suggestions and constructive 
criticisms on the work. 
Special thanks to Frau Schrezenmeir and Frau Manglkammer who helped me get through 
with all administrative procedures. 
I extend my thanks to all the members of the KMOLBI for the wonderful and friendly 
working atmosphere. I am grateful to all the friends in Munich and in other parts of Germany 
for making life enjoyable and adventurous during my entire stay. A special thanks to Cristina 
Rico Garcia for being such a wonderful friend and the time we spent together while staying 
with her during the final months of my tenure. 
I would like to acknowledge Rajesh, my “soul” reason to come to Germany, for the 
discussions, suggestions and troubleshooting he offered throughout the period of this study 
and for the life, dreams, friendship and love that we share. I am grateful to him for being there 
for me and helping me bounce back on track whenever I felt down and assuring me always 
“things will fall into place” during difficult times. 
I offer my gratitude to my parents for their huge support and motivation. I thank my father 
for the constant support and guidance he offered and for his gentle reminder that he believes 
that I could succeed in whatever I undertake. I am grateful to my mom, my best friend and 
mentor for teaching me everything I need, to face all challenges in life. I thank her for being 
here in Germany in the grueling final months of my PhD providing me immense moral 
support and help with mundane day to day tasks. I thank my brother and sister for their 
enormous support and for giving me the encouragement to never give up. Finally I am 
grateful to God, whose Grace, has lead me to where I stand today. 
 
 117 
Ehrenwörtliche Erklärung  
Ich versichere hiermit ehrenwörtlich, dass die Dissertation von mir selbstständig, ohne 
unerlaubte Beihilfe angefertigt worden ist. Diese Arbeit hat in gleicher oder ähnlicher Form 
noch keiner anderen Prüfungsbehörde vorgelegen. 
 
München, den 15. Januar 2009 
 
 
Sushmita Gowri Sreekumar 
 
 
 
Declaration 
 
I hereby declare that this thesis is the result of independent work done by me without any 
unauthorised source of assistance. This work, in the same or a similar form, has not been 
submitted to any other board of examination. 
 
 
Munich, 15
th
 January, 2009 
 
 
Sushmita Gowri Sreekumar 
 
 
 118 
Curriculum vitae 
Personal Profile: 
Name   Sushmita Gowri Sreekumar 
Date of Birth  4th of February, 1978 
Place of Birth: Chennai, India 
Citizenship:  Indian 
*************************************************************************** 
Academic Profile: 
Schooling (1984-1994)  
Rosary Matriculation Higher Secondary School, Chennai, India 
 
Matriculation Examination (1994) 
Board of Matriculation Examination, Tamil Nadu, India 
 
Higher Secondary School Leaving Certificate in science (1994-1996) 
Tamil Nadu State Board of Examinations, India 
 
Bachelor of Science (1996-1999) 
Guru Nanak College, University of Madras, India 
 
Master of Science (2000-2002) 
Department of Life Sciences, University of Madras, India 
 
Junior Research Fellow (2003-2004) 
National Center for Biological Sciences, Bangalore, India 
 
Doctoral studies (2005 – 2009) 
Faculty of Biology, Ludwig-Maximilians University, 
Helmhotz Zentrum, Munich, Germany 
